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Abstract 
The aims of this study were to examine whether there are differences in 
medication management between older and younger adults living with Human 
Immunodeficiency Virus and to examine the relationship between age and personal 
factors including cognitive ability, depression and self-efficacy on medication 
management.  
The research utilized a descriptive-correlational, cross-sectional design to 
compare medication management between older and younger adults living with HIV and 
to describe differences in predictive factors of cognition, depression, and self-efficacy on 
medication management ability between older and younger adults living with HIV. 
Results indicate both older and younger adults have high rates of mild cognitive 
impairment, high rates of depression, and high self-efficacy, and both groups have poor 
medication management ability. In both older and younger adults cognitive ability and 
depression were predictors of medication management, and each factor was a much 
stronger predictor for older adults. Overall cognitive ability was the best predictor of 
medication management for both older and younger adults. 
This research contributes to nursing knowledge in that it helps to identify 
predictive factors impacting medication management in older and younger adults living 
with HIV. The older adult with HIV demographic is one of the fastest growing segments 
of persons with HIV, and these individuals have been under represented in previous 
research. Determining which factors predict medication management, and what is unique 
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about these factors in the older population of persons living with HIV will contribute to 
nurses’ and other healthcare workers’ ability to care for this growing population. 
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Statement of the Problem 
 Currently, more than one million people in the United States are living with 
Human Immunodeficiency Virus (HIV), the virus that causes Acquired Immune 
Deficiency Syndrome (AIDS), and each year another 50,000 new cases are diagnosed 
(Prejean et al., 2011). The virus attacks the immune system and people succumb to 
infections that they can no longer fight off. Not much more than a decade ago, an HIV 
infection was tantamount to a death sentence. More than 620,000 deaths have been 
attributed to the disease since it was first identified in 1981 (Prejean et al., 2011). In spite 
of the tremendous progress that has been made in diagnosis and treatment, in 2009, the 
most recent year for which data is available, there were still more than 17,000 deaths 
attributed to AIDS (CDC, 2011a). 
Today, with early diagnosis, and effective antiretroviral therapy (ART), a HIV 
diagnosis is no longer a death sentence. When used properly, ART halts the progression 
of the virus and keeps HIV from progressing to AIDS. Medications for HIV only work if 
they are taken correctly 90-95% of the time (Bartlett, 2002). Taking medication correctly 
90-95% of the time would be a very difficult task for anyone, but may present a more 
formidable task for older persons with HIV because of other risk factors prevalent in this 
population, including cognitive ability, depression, and low self-efficacy, all of which 
complicate medication management. 
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 This research considered whether the ability to manage medications differs 
between older and younger adults living with HIV, and if so, which specific factors 
accounted for or contributed to the age-related differences. This area of study is important 
because advances in medical research and the development of new medications increase 
the life expectancy of adults living with HIV. But an increased life expectancy in 
individuals with HIV depends, in part, upon the individual’s ability and desire to stick 
with a tedious, rigorous medication schedule for the rest of his or her life. If advancing 
age in HIV patients affects medication management, then it would be important to 
identify specific factors that could explain the age-related difference. Once identified, 
nurses and other healthcare providers could consider these factors as they create 
strategies related to medication management and that will enable patients to take their 
medications correctly at least 90-95% of the time.  
Background and Definitions 
This research examined whether there are differences in medication management 
between older and younger adults living with HIV. Before delving further into the 
problem, it would be useful to provide definitions for generally used terms.  
Older adults with HIV are defined as those individuals 50 years of age and 
older. This is the definition used by the Centers for Disease Control and Prevention 
(CDC) and it is the most frequently used definition in HIV research when studying older 
adults (Avelino-Silva, Ho, Avelino-Silva, & Santos, 2011; CDC, 1993; Gebo, 2006; 
Joyce, Goldman, Leibowitz, Alper,t & Bao, 2005). Younger adults with HIV are 
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defined as individuals between the ages of 18 and 49, the age range commonly used in 
HIV research.  
Self-efficacy is described as a person’s confidence in their ability to perform a 
particular behavior (Bandura, 1997). High self-efficacy along with cognitive ability and a 
low level of depression can overcome environmental barriers in order to effectively 
manage medications (Bandura, 1989). Self-efficacy is a major construct of Social 
Cognitive Theory. According to Bandura (1989), self-efficacy beliefs are what determine 
a person’s level of motivation and thereby influence the effort a person will exert on a 
particular task. When a person has a strong belief in their ability to perform a task, they 
will endure in spite of difficulties they encounter. However, a person who doubts their 
ability to successfully perform a task will limit their effort or may eventually abort the 
attempt altogether when confronted with adversity (Bandura, 1989).  
Medication management is defined as a desire and an ability to adhere to a 
medication regimen (Madigan, Farris, Wiens, & Johnson, 2003). Medication 
management may be adversely affected by age. Cognitive ability, depression, and self-
efficacy, measurable factors in older persons with HIV have been shown to adversely 
affect medication management (DiMatteo, 2004; Dunbar-Jacob & Mortimer-Stephens, 
2001; Gellad, Grenard, & Marcum, 2011). 
Over time the preferred term used when referring to following a medication 
treatment has changed. Compliance, a term frequently used in the past, has fallen out of 
favor because of the perception that it is a value judgment on the patient’s behavior 
(Wood et al., 2002). Adherence, a term more commonly used today, is defined as the 
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extent to which patients take medications as prescribed by their health care providers 
(Osterberg, 2005). Medication management, the term used in this study was chosen 
because it incorporates both desire and ability to take medications correctly. 
Cognitive Decline is described as a decrease in memory, language, thinking, and 
judgment. Cognitive decline can decrease the ability to perform tasks associated with 
daily functioning (Valcour et al., 2011). In the general population age has been an 
important predictor of cognitive decline (Bishop, Lu, & Yanker, 2010; Salthouse, 2009). 
According to Salthouse, cognitive decline begins in early adulthood and accelerates for 
adults after age 60. Approximately 50% of adults over age 85 are afflicted with cognitive 
decline and dementia (Bishop, Lu, & Yanker., 2010). Contrast this with the research on 
older persons with HIV, where studies are finding that cognitive decline in adults with 
HIV is more extensive and begins at an earlier age than in the general population (Ances 
et al., 2010). Nurses and other healthcare providers may not be aware of the prevalence 
and early onset of cognitive decline in the older HIV population, They may overlook 
subtle signs of decline and miss early opportunities to assess its impact on medication 
management. 
Ances et al. (2010) and Malaspina et al. (2011) found high rates of cognitive 
decline in adults with HIV as young as 45 years of age. This cognitive decline was 
related to brain function. The brain function of persons with HIV was found to be similar 
to that of persons 15 to 20 years older who did not have HIV (Ances, 2010). Malaspina et 
al. found cognitive decline associated with increased depression and decreased 
medication management. These findings suggest that cognitive decline at an early age has 
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implications for medication management in the population of older persons living with 
HIV.  
Depression is defined as a mental state or chronic mental disorder characterized 
by feelings of sadness, loneliness, despair, low self-esteem, and self-reproach (Stedman, 
2011) Depression is not unique to persons with HIV. Depression affects people 
throughout society across all socio-demographic groups. But the rates of depression in 
adults with HIV appear to be higher than in the general population, and even higher than 
rates in other chronic diseases (Valente, 2003). The high rate of depression is of concern 
because depression has been shown to affect medication management in persons living 
with HIV (Voss, Portillo, Holzemer, & Dodd, 2007).  
According to the CDC (2010a), 9% of adults in the United States suffer from 
depression. The rate of depression in older adults is higher than the rate in the overall 
population, with about 15% of older adults affected by depression (Ciechanowski et al., 
2004). Studies have shown a higher level of depression in persons with chronic illnesses, 
and rates in older adults with chronic illnesses range from 20 to nearly 50% (Harpole et 
al., 2005; Krishnan et al., 2002; Reich 2008). In persons with HIV depressive symptoms 
that are clinically significant are common, with rates reported as high as 30% (Bagulho, 
2002; Lyness et al., 2007). In older persons with HIV, depression rates higher than 50% 
have been reported (Kilbourne et al., 2002; Valente, 2003; Voss et al., 2007).  
The rate of depression in the older HIV population is explained in part by the 
chronic nature of HIV disease, yet other factors are at play resulting in rates higher than 
in other chronic diseases. Studies by Emlet (2007) found that the stigma associated with 
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HIV contributes to an increase in depression rates in this cohort. Studies specifically 
examining depression in older adults living with HIV have found that an association 
exists between depression and decline in cognitive abilities (Voss et al., 2007). The 
clinical implications of high depression rates in older patients with HIV and the 
understanding that depression can affect medication management should signal nurses to 
be vigilant in assessing depression in their older patients with HIV. 
Significance of Medication Management  
Medication management of antiretroviral therapy (ART) is one of the strongest 
predictors of whether an individual’s HIV will progress to AIDS and ultimately lead to 
death (Battaglioli-DeNero, 2006). Where it is available, ART is commonly prescribed to 
manage HIV. Research studies have shown that the medications must be taken correctly 
95% of the time to keep the HIV virus fully suppressed in the body (Bartlett, 2002; 
Battaglioli-DeNero; Chesney et al., 2000). Medication management has been identified 
as an important component of taking medications correctly in persons living with HIV 
(Albert et al., 1999; Sorensen, Mascovich, Wall, Dephilippis, Batki, & Chesney, 1998).  
Despite the importance of ART in effectively managing HIV, few studies have 
focused on medication management and its role in taking medications correctly, and 
within those few studies, the population of older adults living with HIV has not been a 
focus of the research. The lack of research on aging and medication management is a 
significant omission given that persons over the age of 50 are the fastest growing segment 
of persons living with HIV. In 2005 persons over the age of 50 accounted for only 15% 
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of new HIV diagnoses (CDC, 2008a). It is estimated that by 2015 over half of all persons 
living with HIV will be 50 years of age or older (CDC, 2008c).  
Studies have found that medication management is affected by factors such as 
cognitive ability, depression, and self-efficacy (Malaspina et al., 2011; Sarkar, Fisher, & 
Schillinger, 2006; Voss et al., 2007). Studies have also found that cognitive ability, 
depression, and self-efficacy are worse in older adults with HIV (Ances et al., 2010; 
Justice et al. 2004; Karpiak & Shippy, 2006; & Woodward & Wallston, 1987). However 
there is a gap in the research. To fill that gap this study will consider if cognitive ability, 
depression and self-efficacy affect medication management differently in older adults 
with HIV than in younger adults with HIV. This study will contribute to knowledge in 
HIV and aging research by studying cognitive ability, depression and self-efficacy to 
determine if their influence on the older population makes their effect on medication 
management different. 
Human Immunodeficiency Virus 
Human Immunodeficiency Virus is a difficult disease to oversee. Medication 
management involves adapting life-altering changes in order to successfully manage HIV 
disease. If persons are ill-equipped to manage their medications, it is difficult to take 
them correctly 90-95% of the time, and overall health will suffer. Self-efficacy is a 
person’s belief in their ability to succeed in a particular situation (Bandura, 1995). This 
belief is what determines a person’s level of motivation and thereby influences the effort 
a person will exert on a particular task (Bandura, 1989). This belief in the ability to 
successfully manage medications is an integral part of disease management. Nurses who 
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educate patients about their medications and the importance of medication management 
can increase self-efficacy in their patients. High self-efficacy is associated with improved 
self-management in adults with chronic diseases (Brekke, Hjortdahl, & Kvien, 2001; 
Grembowski et al., 1993; Sarkar, Fisher, & Schillinger, 2006). A low sense of self-
efficacy is associated with the development of depression and anxiety (Bandura, 1993). 
Bandura (1993) found that people do not perform well if they lack the necessary skills, or 
if they have the skills but lack the efficacy needed to utilize them. Self-efficacy has been 
found to mediate the impact of low literacy in medication management (Wolf, Davis, 
Osborn, Skripkauskas, Bennett, & Makoul, 2007). 
Theoretical Framework 
Social Cognitive Theory is the theoretical framework used in this study to 
examine medication management in adults living with HIV. The study also examines the 
effects of specific factors (i.e., cognitive ability, depression, and self-efficacy) on 
medication management in older and younger adults in order to determine whether 
specific factors can predict age-related differences in medication management in persons 
living with HIV. 
Statement of the Purpose 
The aims of this study were to examine whether there are differences in 
medication management between older and younger adults living with HIV and examine 
the relationship between age and personal factors including cognitive ability, depression 
and self-efficacy on medication management. Influences on medication management for 
older adults living with HIV become important to nurses and other healthcare providers 
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as they consider strategies to promote medication management for their patients living 
with HIV. 
Study aim one was achieved through research questions one. Study aim two was 
achieved through research questions two, three and four. 
The specific questions to be answered were: 
Question 1: Is there a difference in the medication management ability between older 
and younger adults living with HIV? 
Question 2: Are there differences in cognitive ability, depression, or self-efficacy 
between older and younger adults living with HIV? 
Question 3: What are the associations between personal factors (cognitive ability, 
depression, and self-efficacy) and medication management among older and younger 
adults living with HIV, respectively?  
Question 4: Which personal factors (cognitive ability, depression, and self-efficacy) are 
the best predictors of medication management among adults living with HIV, controlling 
for age as a covariate?  
Significance of the Problem 
Recent advances in early diagnosis and medications create the opportunity for 
persons with HIV to live to an advanced age. Adults over the age of 50 are expected to 
make up more than half of all persons living with HIV by the year 2015 (CDC, 2008c). A 
longer life expectancy creates new challenges for older adults living with HIV, and for 
their health care providers. Much of HIV care is now managed on an outpatient basis and 
patients are only seen for healthcare visits once every three or four months (Uphold & 
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Mkanta, 2005). Between visits patients are responsible for maintaining their health. An 
important component of health maintenance is medication management. Nurses play a 
vital role in educating their patients as to the importance of taking charge of their 
physical, psychological, and emotional health. Nurses emphasize the importance of 
medication management, and encourage patients to function independently in refilling 
prescriptions promptly, assessing side effects of their medications, and notifying the 
healthcare team when problems develop.  Mastering these skills may only be possible if 
patients are healthy enough both physically and psychologically to master these skills 
(Hinkin et al., 2002).  
Pharmacological advances have contributed to the development of simpler 
medication regimens for persons with HIV. Paradoxically, improved medication 
management has not followed. This lack of improvement is an issue because when a 
person stops taking medications or takes them incorrectly or inconsistently, the HIV virus 
becomes resistant to those medications and different, more toxic medications may be 
needed to combat the newly mutated virus (Robbins et al., 2003). Currently, the second-
line and third-line medication treatments available come with an increased pill burden, 
more complicated dosing regimens, and an increase in the number and severity of 
toxicities, all of which complicate medication management.  
Older adults may also have comorbidities that require more complicated HIV 
medication regimens (Grabar, Weiss, & Costagliola, 2006). Drug to drug interactions 
between HIV medications and other medications may arise. Additionally, HIV 
medications sometimes exacerbate conditions, such as cardiac and metabolic problems 
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that are already more common in the older population (Grabar et al., 2006). Determining 
what impedes older adults from managing their medications is an area in need of further 
research. If nurses better understood medication management in the older HIV population 
and could identify clinical factors associated with medication management problems, 
they may be able to intervene to improve medication management before medication 
changes become necessary. 
Older individuals may be dealing with cognitive decline, depression, or other 
comorbidities that increase pill burden and increase dosing schedule, thereby 
complicating the already difficult task of managing medications effectively. Cognitive 
decline and depression, along with a more complicated medication schedule potentially 
present significant and critical issues for older individuals living with HIV because 
medication management is essential for medications to be effective. Determining if 
certain variables are associated with medication management may offer nurses insight 
into how to focus education and intervention efforts to increase the ability to manage 
medications in older adults living with HIV. 
The Variables 
Four variables were selected for this study. The three independent variables (ie: 
cognitive ability, depression and self-efficacy) were selected because they have been 
shown to have a greater impact on older adults with HIV than on younger adults 
(Treisman, Angelino, & Hutton, 2001). These independent variables have also been 
shown to have an effect on medication management in previous research (Clark & 
Dodge, 1999; Knowlton, Curry, Hua, & Wissow, 2009; Selnes, 2002). Medication 
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management was chosen as the dependent variable because of its importance in 
promoting health in persons with HIV. Medication management is an area of HIV care 
where nurses play an important role. By learning more about what factors influence 
medication management nurses will be better equipped to recognize when medication 
management may be an obstacle for their patients, and can use this knowledge to be 
proactive in improving medication management. The variables used in this study, and the 
instrument used to measure each variable are discussed in Table 1. 











Cognitive ability predicts 
performance (Hunter, 2004). 
Cognitive decline is seen nearly 
twice as often in older persons with 
HIV compared to younger persons 
(Hinkin, Castellon, Atkinson, and 
Goodkin, 2001). Hinkin et al. 
(2004) found that older persons 
without cognitive decline were 
better able to manage their 
medications. 
The brain-based skills needed to 
carry out tasks, things people are 
cable of doing (Mayer & Massa, 
2003). Cognitive decline involves 
changes in memory, language, 
thinking, and judgment. 
Cognitive decline can decrease 
the ability to perform tasks 
associated with daily functioning 
(Valcour et al., 2011).  
Depression   
Center for 
Epidemiologic 
Common in persons living with 
HIV. Several studies report that 
more than half of persons living 
with HIV suffer from depression 
A mental state or chronic mental 
disorder characterized by feelings 
of sadness, loneliness, despair, 
low self-esteem, and self-




Scale      
(CES-D) 
and the rate increases in the aging 
population (Grov et al., 2010, Yun, 
Maravi, Kobayashi, Barton, & 
Davidson, 2005). As studies by 
Grov et al. (2010) and Karpiak and 
Shippy (2006) have shown, 
depression affects a persons’s 
ability to perform activities of daily 
living (ADLs), including 
medication management.  
reproach; accompanying signs 
include psychomotor retardation 
(or less frequently agitation), 
withdrawal from social contact, 
and vegetative states such as loss 








Vital to taking medication correctly 
90-95% of the time. Identifying 
factors that affect medication 
management, especially in the older 
population with HIV, will provide 
nurses and other healthcare 
providers with new information that 
can be used to formulate plans to 
improve patients’ medication 
management. 
For purposes of this study, 
medication management is 
defined as a person’s desire and 
ability to utilize their cognitive 
and functional ability to comply 
with their medication regimen 







Predictive of medication 
management in chronic diseases 
(Clark & Dodge, 1999). Later 
studies that looked specifically at 
HIV also found self-efficacy to be 
associated with medication 
management (Barclay et al., 2007; 
Gifford et al., 2000; Johnson et al., 
According to Bandura (1995), 
self-efficacy is a person’s belief 
in their ability to organize and 
execute a series of actions 
necessary to accomplish a task or 
goal.  
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2003).  Though the importance of 
self-efficacy in medication 
management has long been 
recognized, it is not usually 
assessed during healthcare visits. 
Such failure in assessment deprives 
nurses of the opportunity to 
determine the effect of this variable 
on a patient’s ability to manage 
their medications. 
 
Overview of Remaining Chapters 
 Each chapter in this dissertation begins with an introductory section that identifies 
the purpose of the study and states the research questions. 
 Chapter one sets the tone for the research by providing a statement of the problem 
being studied, the purpose of the study, the research questions being asked, and important 
definitions. Chapter one also provides an introduction to Social Cognitive Theory, the 
theoretical framework used in the research study. 
 Chapter two begins with a brief history of HIV in order to present the scope of the 
disease. This chapter examines the body of literature focused on the depth and the 
breadth of the disease. The literature focuses on aging with HIV and special attention is 
given to the physiological and psychosocial literature that has shown cognitive decline, 
depression and low self-efficacy to be present in higher rates in the older HIV population. 
Literature that supports the importance of medication management in maintaining health 
in persons living with HIV is reviewed, along with a discussion of barriers to medication 
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management. The theoretical foundation for this study is Bandura’s Social Cognitive 
Theory, and in chapter two there will be a discussion of how it forms the underpinning 
for this study. 
 Chapter three describes the design and methodology used in this study. The 
instruments used in this study are explained in detail, as are the rationales for the use of 
each specific instrument, along with the validity and reliability of each instrument. The 
chapter contains information about the data collection process; the methods used to 
collect, manage and analyze the data will be explained in detail. The chapter contains 
information about the research setting, and human subjects’ protection, along with the 
time frame of the study. Finally, strengths and limitations of the study are discussed in 
this chapter. 
Chapter four contains the findings of the study. It presents the results of the 
statistical analyses procedures used to answer each of the questions. It is organized into 
five sections: 1) recruitment and data management, 2) sample characteristics, 3) quality 
of measures, 4) results to related questions, and 5) discussion. 
 Chapter five summarizes the findings from the study and discusses the 
implications and limitations. Lastly, suggestions for future research are presented. 
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Chapter 2 
Review of the Literature 
The primary aim of this research was to examine if medication management is 
different for older adults living with Human Immunodeficiency Virus (HIV) compared to 
younger adults living with HIV. The secondary aim was to examine the relationship 
between age, personal factors (cognitive ability, depression, and self-efficacy) and 
medication management among participants. The two study aims were achieved through 
the following research questions. 
Question 1: Is there a difference in the medication management ability between older 
and younger adults living with HIV? 
Question 2: Are there differences in cognitive ability, depression, or self-efficacy 
between older and younger adults living with HIV? 
Question 3: What are the associations between personal factors (cognitive ability, 
depression, and self-efficacy) and medication management among older and younger 
adults living with HIV, respectively?  
Question 4: Which personal factors (cognitive ability, depression, and self-efficacy) are 
the best predictors of medication management among adults living with HIV, controlling 
for age as a covariate?  
This area of study has become increasingly significant. Advances in medical 
research and the development of new medications have slowed the progression of the 
HIV virus and accompanying opportunistic infections, and thereby increased the life 
expectancy of adults living with HIV. An increased life expectancy depends, in part, 
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upon an individual’s ability and desire to stick with a difficult, rigorous medication 
schedule for the rest of his or her life. If advancing age in HIV patients affects one’s 
ability to manage medications then it would be important to identify specific factors that 
are associated with the age-related differences. Once identified, nurses and other 
healthcare providers could consider these factors as they formulate strategies related to 
medication management that will enable patients to take their medications correctly at 
least 90-95% of the time.  
Introduction 
When HIV was first identified in the early 1980s no medications were available 
that could stop HIV from decimating the immune system and taking over the body 
(Brodt, 1997). Even persons receiving the best medical care available at the time incurred 
opportunistic infections that eventually destroyed a weakened immune system and their 
HIV disease progressed to Acquired Immune Deficiency Syndrome (AIDS) (Wood, 
Whittet, & Bradbeer, 1997).  
In the past thirty years, significant advances have been made in detection and 
treatment of HIV and the accompanying opportunistic infections. With the advent of 
antiretroviral therapy (ART) in the late 1980s, healthcare providers were finally able to 
provide patients with medications that could prolong their lives (CDC, 2007). Still, ART 
was not a cure and the toxic side effects of the available medications made them difficult 
to take consistently. Side effects of ART included anemia, neuropathy, and severe 
gastrointestinal disturbances (Carr & Cooper, 2000). Many of those living with HIV were 
unable to tolerate the side effects of their medications and they eventually stopped taking 
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them, even though they may have known the consequences of not taking these 
medications.  
The advent of new medications with less toxic side effects have helped transform 
a once fatal disease into a chronic, manageable disease. This meant HIV infection was no 
longer an automatic death sentence and persons living with HIV were now able to attain a 
near-normal life expectancy (Bhaskaran, et al., 2008; Deeks & Phillips, 2009; Stoff, 
Khalsa, Monjan, & Portegies, 2004). Yet survival remains dependent upon a person’s 
ability and willingness to take their prescriptive medications despite the challenge this 
task presents.  
There are factors that contribute to a person’s inability to manage their 
medications effectively. Three known factors that adversely influence medication 
management are cognitive ability, depression, and self-efficacy. Adults with HIV 
experience high rates of depression. They also experience cognitive decline earlier than 
the general population. These conditions are exacerbated in older persons with HIV 
(Grov, et al., 2010; Valcour, Shikuma, Shiramizu et al., 2004). These findings suggest 
that older adults living with HIV may have more difficulty with medication management 
than their younger counterparts. 
While medical advances in treating HIV over the past thirty years represent the 
most dramatic change in this epidemic, other changes have also occurred. No longer is 
HIV considered a disease of young gay men. The demographics of the disease have 
changed.  The disease, HIV, affects men and women, gay and straight. Men who have sex 
with men remain the group most affected by HIV, but other groups, especially persons of 
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color have also been disproportionately impacted by this disease (Hutchinson et al., 
2006).  
 The population of older adults living with HIV has steadily increased in a 
relatively short period of time. In 2005, adults aged fifty and over accounted for 15% of 
the new HIV/AIDS diagnoses and 24% of persons living with HIV (CDC, 2008a). By 
2015, it is expected that more than 50% of persons living with HIV will be over the age 
of fifty. This is a marked change from the early years of the HIV epidemic. As recently as 
2000, only 6.5% of persons living with HIV were aged 55 or older (CDC, 2004). 
 The number of women living with HIV has increased as well. In fact, women 
have emerged as one of the fastest growing groups within the population of older adults 
with HIV. In 2007, over 25% of new HIV diagnoses were in women (CDC, 2010b). 
According to the most recent data available, women now account for approximately one 
quarter of the HIV/AIDS cases in the United States (CDC, 2008b). This represents a 
dramatic increase from just 14% of the cases a decade ago. The number of AIDS cases in 
women over the age of 50 has nearly tripled in the last 10 years and women aged 50 and 
over now account for more than 10% of women living with AIDS in the United States 
(CDC, 2008b).  
Both Black men and women have been heavily impacted by HIV. Blacks account 
for nearly half of all new HIV infections despite making up 12% of the total United 
States population (Hall et al., 2008). As the number of infections in women continues to 
climb, women of color are affected disproportionately. Infection rates for Black and 
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Hispanic women far exceed those for White women in both older and younger 
populations (CDC, 2011a).  
Progress in the fight against HIV has been made on fronts other than more 
effective medications. An important change in the evolution of HIV care is that testing 
for the virus is becoming a routine part of medical care in many healthcare facilities. In 
the past HIV testing was only discussed with those persons deemed to be at risk, and not 
offered to others (Branson et al., 2006). This change has enabled infections to be 
discovered earlier and prior to progressing to AIDS (Branson et al., 2006). With early 
treatment and better medications available people are able to resist the opportunistic 
infections that were common and often fatal only a decade ago.  
Despite progress made in the fight against HIV, the older population has seen an 
increase in HIV infections and a higher percentage of older persons with HIV have been 
diagnosed with AIDS compared to the younger population. Early testing, essential in 
identifying infections, has not been adopted in the older population to the same degree it 
has in the younger population. Lack of testing creates an unnecessary barrier to early 
detection and entry into care for older adults. The most recent CDC guidelines (CDC, 
2006a) recommend routine opt-out HIV testing for all persons between the ages of 13 and 
64. Opt-out testing means a person will be tested for HIV unless they specifically refuse 
the test. The clinical goal of opt-out testing is early diagnosis and entry into care. Testing 
for persons age 65 and older has not increased to the same degree it has in the younger 
age groups since guidelines have not changed for this age group (Tangredi, Danvers, 
Molony, & Williams, 2008).  
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Older adults living with HIV have in many ways remained an invisible element in 
the HIV/AIDS epidemic in spite of their increasing numbers. Older adults are an 
understudied and underserved group. Clinical trials research on the effectiveness of new 
HIV medications too often excludes older adults from participation. This limits 
knowledge of how medications may work differently in the aging population (Linsk, 
2000; Manfredi, 2003). Prevention messages continue to target younger adults (Mack & 
Ory, 2003). The words and the images are geared toward youth to the exclusion of older 
adults. Health care providers continue to be reluctant to discuss sex and HIV risk factors 
with their older patients (Sormanti & Shibusawa, 2007). Additionally an HIV diagnosis 
may be delayed in older persons. Symptoms of HIV, such as weight loss and fatigue, can 
be similar to ordinary conditions of aging (Siegel, Schrimshaw, & Dean, 1999). These 
circumstances contribute to older adults being diagnosed later in the disease process, 
making treatment complex.  
This chapter contains an overview of research on HIV and of aging. The literature 
review includes a discussion of studies addressing physiological and psychosocial aspects 
of aging with HIV and how these physiological and psychosocial aspects affect 
medication management. The discussion incorporates research studies on cognitive 
ability, depression, and self-efficacy in older and younger HIV populations, and the effect 
cognitive ability, depression and self-efficacy have on medication management. This 
chapter concludes with a discussion of Social Cognitive Theory as a framework for 
studying medication management within this research. 
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Aging with HIV 
Thirty years into the HIV epidemic we are recognizing that one of the ripple 
effects of treatment advances in HIV is the increasing numbers of older adults living with 
the disease (CDC, 2008c). Based on current projections, more than 50% of the HIV 
population will be aged 50 years and older by the year 2015 (CDC, 2008c). This figure 
includes both those infected with HIV at a younger age who are now living longer and 
adults not diagnosed with HIV until after the age of 50.  
The CDC defines older adults with HIV as those 50 years of age and older (CDC, 
1993). Early in the epidemic the CDC chose the age of 50 years and older to represent an 
older cohort. At that time age 50 was much older than the mean age of persons living 
with HIV (Gebo, 2006). This age made sense because as people reached age 50 they 
experienced changes related to aging. As scientists and healthcare providers grappled 
with identifying disease characteristics, this age delineation made sense, the age of 50 
and older continues to be used in much of the HIV research focusing on older adults 
(Avelino-Silva, Ho, Avelino-Silva, & Santos, 2011; CDC, 1993; Gebo, 2006; Joyce, 
Goldman, Leibowitz, Alpert, & Bao, 2005).  
Recognition of the profound impact that HIV has on the older population is a 
relatively recent phenomenon (Emlet, 2006b; Gebo, 2006; Shah & Mildvan, 2006). The 
main body of literature on aging with HIV has been developed only within the past 
decade. Prior to that time HIV was considered a disease of young persons (Fenton, 2007; 
Riley, 1989). It was thought that older adults generally did not engage in behaviors that 
would put them at risk for HIV infection (Emlet, 2006b). Transmission of HIV occurs 
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primarily through unsafe sexual practices and sharing of dirty needles by intravenous 
drug users. Both of these practices are considered activities engaged in by younger 
persons. Therefore medical and psychological considerations, prevention strategies, and 
research dollars were targeted at youth, ignoring the older population. 
Another reason that older adults with HIV were not included in research is that 
there were relatively few older adults available to participate (CDC, 2004). In addition, 
older adults were generally not discussed as a subpopulation when reporting results of 
research trials. This strategy may have been reasonable in the early years of the epidemic. 
At that time due to the combination of young age at time of infection and a short life-
expectancy after diagnosis, few older adults with HIV infection were alive. Because there 
were few treatment options for HIV available there was little practical reason to consider 
age when developing a plan of care for adults with HIV.  
The increase in the number of older adults living with HIV can be attributed in 
large part to the advent and effective use of antiretroviral therapy (ART). In most patients 
with an HIV diagnosis ART is able to bolster the immune system and increase life 
expectancy. The result was that in less than 10 years between 1996 and 2005, life 
expectancy after an HIV diagnosis more than doubled, going from 10 years to over 20 
years (Harrison, Song, & Zang, 2010). The effectiveness of ART has been responsible for 
changing the classification of HIV from a fatal disease to a chronic disease. Currently 
persons infected with HIV at a younger age now have the opportunity to live into old age, 
a phenomenon not seen earlier in the epidemic. 
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 Interestingly there has also been an increase in the number of new HIV infections 
in persons over age 50. The CDC estimates that in 2005 persons over the age of 50 
accounted for about 20% of all new HIV infections (CDC, 2006b). The reasons for this 
increase in new infections in this age group include infrequent condom use and 
inadequate discussion between healthcare providers and older patients about sexual 
practices and HIV risk (Sormanti & Shibusawa, 2007). Condom use is not the norm in 
older adults because pregnancy is no longer a concern and most older adults do not 
consider themselves to be at risk for HIV (Lindau et al., 2007; Önen, Shacham, Stamm, 
& Overton, 2010; Trobst, Herbst, Masters III, & Costa, 2002).  
Studies by Lindau, Leitsch, Lundberg, and Jerome (2006) and Nusbaum, Singh, 
and Pyles (2004) found the majority of sexually active older adults did not discuss sex 
with their healthcare providers. In failing to initiate this discussion, nurses miss out on 
opportunities to assess their older patients risk for HIV and are unable to educate them 
about safer sex practices and the benefits of HIV testing. 
Older adults often underestimate their risk for contracting HIV (Lindau et al., 
2007). In a study by Coleman and Ball (2007) older adults reported multiple sexual 
partners and infrequent condom use, yet despite these risk factors they rated their risk of 
contracting HIV as low. Sormanti and Shibusawa (2007) found that condom use was not 
only associated with younger adults, but with younger persons of higher socioeconomic 
status and a higher level of education. These findings regarding condom use suggest that 
many of those at highest risk for HIV infection, are the very persons least likely to be 
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using condoms (Coleman & Ball, 2007; Winningham, Corwin, Moore, Richter, Sargent, 
& Gore-Felton, 2004).  
Older Black women have been hard hit by HIV. In 2004, HIV infection was the 
leading cause of death for Black women between the ages of 45 and 54 (CDC, 2008b). 
The majority of older Black women are infected with HIV through heterosexual sex 
(CDC, 2008b). Research suggests that many of these women may be ill-equipped to 
protect themselves sexually because they lack power in sexual relationships, and have 
poor sexual negotiation skills (Lindau et al., 2006; Neundorfer, Harris, Britton, & Lynch 
2005). These women also reported drug and alcohol use, physical and sexual abuse, and 
acknowledged taking risks to keep a relationship intact, all circumstances that put them at 
risk for contracting HIV. Jacobs and Thomlison (2009) and Jacobs and Kane (2011) 
found that low self-esteem was a risk factor for HIV in women over age 50, reporting that 
low self-esteem was predictive of increased HIV-risk behaviors. Similar to studies on 
older adults in general, studies focusing on older women found the women had little 
knowledge of how HIV was transmitted, and considered themselves to be at low risk for 
infection (Altschuler, Katz, & Tynan, 2004; Ward, Disch, Schensul, & Levy, 2011).   
As the HIV risk in the older adult population is beginning to be recognized, 
prevention strategies specific to this age group are at last being developed. Testing for 
HIV is beginning to be offered as a routine part of healthcare (AIDS Alert, 2010). Other 
prevention strategies are focusing on raising awareness of HIV in the older adult 
population, including prevention messages that target older adults with both age-
appropriate text and images (Obermeyer & Osborn, 2007).  
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Research on older adults living with HIV is in its infancy. Up until now older 
adults have been cared for and treated for HIV based on research that targeted a much 
younger demographic. Current research is finding differences in older and younger 
persons living with HIV but nurses lack the necessary tools to recognize problems 
specific to older adults. There is a clear and urgent need for the development of 
knowledge regarding whether older adults living with HIV face unique and different 
problems than younger adults with HIV. An area that is in need of research and is vital to 
caring for this emerging demographic is whether there are differences in medication 
management between older and younger adults living with HIV. 
Socio-Economic Factors Affecting Older Persons with HIV 
The aging HIV population is changing. Joyce, Goldman, Leibowitz, and Alpert 
(2005) found two distinct groups of older adults living with HIV: gay men who were 
well-educated and financially stable and persons from some minority groups, especially 
Blacks and Hispanics, with limited education and financial resources. The changing 
demographics of HIV will increase the numbers of persons from these minority groups 
and persons of lower socioeconomic status aging with this disease. As these Black and 
Hispanic groups’ age, public and private financial resources will be increasingly strained. 
Joyce et al. found almost one third of Whites and more than two thirds of Blacks and 
Hispanics over age 50 stopped working within one year of an HIV diagnosis, taxing an 
already overburdened Medicare/Medicaid system. Crystal et al. (2003) found that older 
persons from these minority groups were especially impoverished, which contributes to 
an elevated relative risk of death in persons with HIV.  
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Long-term survivorship of persons with HIV is now commonplace in areas where 
ART is readily available. Long-term survivors are more likely to live in poverty than 
newly infected older adults. Robinson, Petty, Patton, and Kang (2008) compared long-
term survivors and newly infected older adults with HIV. Because of years of living on 
disability, or a decreased ability to work due to illnesses associated with HIV, older long-
term survivors were more likely to live in poverty.  
Wood et al. (2002) found socioeconomic status was strongly associated with HIV-
related mortality. In this study persons of lower socioeconomic status began treatment 
later in the disease course than persons of higher socioeconomic status. Mortality was 
attributed to delayed receipt of ART. One explanation for this disparity in treatment was 
health care providers’ reluctance to prescribe medications because of concerns that poor 
medication management in this less stable group could lead to resistance to medications, 
resulting in fewer treatment options in the future (Wood et al., 2002). However studies 
have shown providers do little better than chance in correctly predicting which patients 
will take their HIV medications as prescribed (Bangsberg et al., 2001). Bogart, Catz, 
Kelly and Benotsch (2001) found healthcare providers may place too much emphasis on 
socioeconomic factors when predicting adherence. 
Unstable housing makes managing HIV a more difficult proposition. Uphold and 
Mkanta (2005) looked specifically at the health care service needs of older adults with 
HIV and found that unstable housing was associated with higher medical costs, poorer 
access to care, and a lack of continuity of care. Studies have found an association 
between unstable housing and medication adherence (Spire et al. 2002; Tobias et al. 
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2007). Stewart, Cianfrini, and Walker (2005) found that unstable housing was associated 
with poorer physical health in persons living with HIV. 
In 1990 the Ryan White Comprehensive AIDS Resources Emergency (CARE) 
Act was implemented to improve quality and access to HIV services for low-income 
persons with HIV. While services improved under this act, they remained unequal for 
disadvantaged persons with HIV (McKinney & Marconi, 2002). Marx, Katz, Parks and 
Gurley (1997), found that in spite of the tremendous influx of government funding, 
uninsured, minorities, and women remained slower to enter into HIV care. Although once 
established in care, access to ART was similar for all groups,  
Older Black men and women with HIV are challenged to successfully manage 
their HIV. A study by Heslin, Andersen, Ettner, and Cunningham (2005) found Black 
patients with HIV less likely than White patients with HIV to have an infectious disease 
specialist providing their HIV care.  Blacks with less education, no health insurance, and 
lower household incomes were least likely to be cared for by a HIV specialist (Heslin et 
al., 2005). Korthuis et al. (2008) found racial disparities in access to care and found that 
these disparities were the result of community-level differences. Blacks living in poor 
urban areas often only had access to inner-city clinics where there are limited resources. 
Both Heslin et al. and Korthuis et al. emphasized that limited access to care resulted in 
poorer outcomes for affected patients.  
 Previous research has shown Blacks and Hispanics have higher levels of 
physician distrust than Whites, and lower socioeconomic status exacerbates this distrust 
(Armstrong, Ravenell, McMurphy, & Putt, 2007). This distrust can result in a delay in 
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diagnosing HIV infections, since persons distrustful of physicians and the healthcare 
system often put off healthcare appointments until they are very sick. Kuo, Haukoos, 
Witt, Babaie, and Lewis (2005) found that older Black men and women who were more 
distrustful of physicians were likely to have a delayed diagnosis of HIV. This delayed 
diagnosis led to poorer outcomes for the affected individuals.  
Antiretroviral Therapy and Medication Management 
The advent of ART has had a dramatic impact on the lives of persons with HIV. 
Successful implementation of ART is responsible for dramatically increasing the life 
span for those persons living with HIV, provided they have access to these medications 
and take them as prescribed by their health care provider (Bhavan et al., 2008). To be 
effective ART must be taken as prescribed 90-95% of the time. A study by Paterson et al. 
(2000) found that only 22% of persons who took their medications correctly 95% of the 
time failed treatment. When medications were taken as prescribed 80 to 94.9% of the 
time 61% failed treatment. And 80% of persons who took medications correctly less than 
80% of the time failed treatment. Treatment failure complicates care for persons with 
HIV. Taking medications incorrectly leads to resistance to entire classes of HIV 
medications, resulting in the need for new medication combinations that are effective in 
suppressing the HIV virus. Patients with adherence rates greater than 95% had 
considerably fewer hospital days than those with less than 95% adherence:  2.6 days per 
1000 days versus 12.9 days per 1000 days (Paterson et al.). Second- and third-line 
medications are used when initial, or first-line treatment fails, and require a difficult 
dosing schedule (DeFino, Clark, Mogyoros, & Shuter, 2004). Medications may need to 
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be taken two or three times a day, they may need to be taken with food, taken on an 
empty stomach, or taken at night. All these requirements make medication management 
difficult. 
Several studies (Cuzin, Delpierre, Gerard, Massip, & Marchou, 2007) found that 
older adults responded just as well to ART as younger adults if treatment was initiated at 
a similar point in the disease process. However, because of the lack of testing for HIV in 
older adults many were diagnosed later in the disease process; leading to disease 
progression and less immune reconstitution. These results confirmed findings from 
earlier studies that emphasize the need to be proactive in recognizing the risk of HIV in 
the older population. Thus reinforcing the need to increase testing in older adults in order 
that infections are detected earlier and treatment initiated in a timely manner (Nogueras et 
al., 2006; Tumbarello et al., 2004).  
Minority groups, including Blacks, Hispanics and women, are disproportionately 
affected by HIV and are less likely to take medications correctly (Osborn, Paasche-
Orlow, Davis, & Wolf, 2007; Siegel, Karus, & Schrimshaw, 2000; Thrasher, Earp, Golin, 
& Zimmer, 2008).  
Several studies found a difference in medication management between Blacks and 
Whites. Osborn, Paasche-Orlow, Davis and Wolf (2007) determined that low health 
literacy inhibited medication management. The authors reported that Blacks were 2.5 
times more likely to take their HIV medications incorrectly than were Whites. Siegel, 
Karus and Schrimshaw (2000) and Thrasher, Earp, Golin and Zimmer (2008) cited lack 
of trust in the healthcare system in reporting that older Black men were less certain they 
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could take ART consistently than were older White men. Berg, Cooperman, Newville 
and Arnsten (2009) and Wolf, Gazmararian and Baker (2005) found self-efficacy affected 
medication management in all cohorts. 
There is no denying the contribution ART has in treating HIV, yet the long-term 
use of these medications have unintended consequences that can cause an increase in  
comorbidities (Grabar et al., 2006). Side effects of HIV medications continue to be 
problematic and contribute to the difficulty of managing medication regimens. Both the 
side effects of the medications themselves and the increase in pill burden due to an 
increase in comorbidities make medication management more difficult. 
The Physiological Impact of Aging and its Effect on Medication Management 
The impact of aging on HIV is multifaceted. The interaction of aging and HIV 
infection is not altogether understood, nor has the scope and impact on the aging 
population been fully realized. Physiological and psychosocial aspects of aging impact 
HIV disease and its treatment. Research is beginning to focus on the impact of aging with 
HIV in the ART era. Earlier research looked at the effect of aging on HIV in the pre-ART 
era. The results of these studies do not accurately reflect current clinical practice where 
ART is used routinely resulting in increased survival (Gebo & Justice, 2009). While the 
significance of aging on HIV is not fully understood, it is becoming apparent that age 
does impact HIV (Bhavan, Kampalath, & Overton, 2008; Gebo & Justice, 2009). This 
section offers an overview of research focused on the physiological impact of aging with 
HIV, with a review of physiological changes that affect medication management. 
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Although the exact reasons are not understood, several studies have found age to 
be an independent predictor of clinical progression in HIV (Babiker, Peto, Porter, 
Walker, & Darbyshire, 2001; Egger et al., 2002). Research has shown that, after adjusting 
for stage of infection at diagnosis, older adults with HIV have a significantly shorter 
survival time compared with younger adults with HIV (CDC, 2006a).  
Factors that contribute to this survival time include delayed diagnosis, ineffective 
therapy, a weakened immune system, and an increase in the number of comorbidities, 
including AIDS-defining illnesses (Emlet, 2004; Kirk & Goetz, 2009; Nguyen & 
Holodniy, 2008; Rickabaugh & Jamieson, 2010; Vance & Robinson, 2004). Studies have 
found that older adults experienced rates of viral suppression similar to those of younger 
adults, yet they have lower levels of CD4 restoration after initiating ART, evidence of a 
less robust immune system (Goetz, Boscardin, Wiley, & Alkasspooles, 2001; Kalayjian, 
et al., 2005). A weakened immune system provides a partial explanation of comorbidities 
found in older adults with HIV. 
Studies show that in addition to less restoration of CD4 counts, older adults do not 
respond to therapy as quickly as younger adults (Silverberg, Leyden et al., 2007; Kirk & 
Goetz, 2009). This suggests that older adults remain in an immunocompromised state 
longer than younger adults after starting ART. This long-term immunocompromised state 
accounts for an increased risk for infections and increased risk for other illnesses 
(Silverberg, Leyden et al., 2007; Kirk & Goetz, 2009). A host of research confirms that 
older age is associated with an increase in morbidity in adults infected with HIV (Butt et 
al., 2001; Hall, McDavid, Ling, & Sloggett, 2006; Inungu, Mokotoff, & Kent, 2001; 
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Keitz et al., 1996). These same studies found that even when CD4 counts were high, 
older adults were more prone to AIDS-defining illnesses than their younger counterparts. 
Infections and other illnesses increase the need for additional medications, leading to an 
increase in the number of medications and the complexity of dosing.  
Results are equivocal as to whether or not an increased pill burden complicates 
medication management (DeFino, Clark, Mogyoros, & Shuter, 2004; Maggiolo et al., 
2002; Mannheimer et al., 2002; Murphy, Roberts, Martin, Marelich, & Hoffman, 2000; 
Stone, Jordan, Tolson, Miller, & Pilon, 2004; Trotta, 2002). Studies looking strictly at the 
pill count found that medication management was not affected by pill burden (DeFino, et 
al., 2004; Mannheimer et al., 2002). While studies looking at pill count and dosing 
frequency found that increased pill burden complicated medication management 
(Maggiolo et al., 2002; Murphy et al., 2000; Stone et al., 2004; Trotta, 2002).   
Recent research finds the aging process accelerated by HIV (Nunez, Armbruster, 
Phillips, & Gale, 2003). Nurses and other healthcare providers unaware of this research 
may be unaware that their patients with HIV are aging faster than their non-infected 
patients, and that this aging may make them more like non-HIV patients who are 10 to 15 
years older (Ances et al., 2010). Bhavan (2008) reports that this accelerated aging results 
in health problems progressing faster, and diseases associated with aging, such as 
cardiovascular disease and hypertension, are more severe when found in combination 
with HIV disease.  
A variety of health conditions are associated with the aging HIV population. 
Diseases such as coronary artery disease, diabetes, hypertension, hypercholesterolemia 
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and osteoporosis are more common as persons with HIV age (Vance, Mugavero, Willig, 
Raper, & Saag, 2011). Additionally, ART itself is associated with peripheral neuropathy 
and cardiovascular disease (Grabar et al., 2006). Not only are diseases associated with 
aging more common in persons with HIV, but many are being diagnosed at a younger age 
in adults living with HIV compared with the general population (Deeks & Phillips, 2009).  
Comorbidities 
Adults with HIV have more diseases than adults in the general population and 
many of these diseases are not specifically HIV- or AIDS-related (Deeks & Phillips, 
2009; Goulet et al., 2007). Older adults with HIV report four times the number of 
comorbidities as younger adults with HIV (Shah & Mildvan, 2006). Comorbidities 
complicate medication management by impacting overall health, decreasing the ability to 
perform activities of daily living (ADLs), and increasing pill burden (Roberts et al., 
2006). As the number of older adults living with HIV increases, comorbidities become a 
major component of care. 
Among the more common comorbidities prevalent in older adults with HIV are: 
cardiovascular disease, bone disease, various cancers, peripheral neuropathy, frailty, and 
neurocognitive disorders (Bhavan et al., 2008; Önen, Overton et al., 2010).  
Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause of death in the United States. 
Many of the medications used to treat the HIV virus, and the virus itself increase the risk 
for CVD. Several studies found increased risk for CVD associated with the use of ART 
(Currier et al., 2003; Salyer, Lyon, Settle, Elswick, & Rackley, 2006). Fat redistribution, 
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an unwanted side effect of HIV and HIV medications, was a predictor of cardiovascular 
risk in patients taking ART (Currier et al., 2003; Friss-Moller et al., 2003; Friss-Moller et 
al., 2007; Hadigan et al., 2001; Hadigan et al., 2003).  
Smoking is a known risk factor for cardiovascular disease, and persons living 
with HIV have been found to be smokers. Studies found smoking rates ranging from 40 
to 74% in persons with HIV (Burkhalter, Springer, Chhabra, Ostroff, & Rapkin, 2005; 
Mamary, Bahrs, & Martinez, 2002; Miguez-Burbano et al., 2005; Vance, 2011; Webb, 
Vanable, Carey, & Blair, 2007). This compares to a rate of approximately 20% in the 
general population (CDC, 2011b).  
Several studies have found an association between smoking and poor medication 
management (Feldman et al., 2006; Shutter & Bernstein, 2008). Feldman et al. (2006) 
found 68% of smokers report taking medications correctly 95% of the time, while 77% of 
non-smokers reported taking their medications correctly 95% of the time. Smokers fared 
worse in a study by Shutter and Bernstein (2008), where current smokers took their 
medications correctly 63.5% of the time compared to a rate of 84.8% in the non-smokers.  
Bone Disease 
Older adults with HIV are diagnosed with bone diseases at a higher rate than older 
adults in the general population (Arnsten et al., 2007; Triant, Brown, Lee & Grinspoon, 
2008). Bone fractures are a concern for older adults with HIV. Fractures can start a 
cascade of problems including frailty, decrease in quality of life, and a decrease in ADLs, 
including medication management. Arnsten et al. (2007) and Triant et al. (2008) found 
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fracture rates in older adults with HIV increased when compared to non-HIV-infected 
persons, and these differences increased as the ages of patients increased.  
Studies suggest that bone disease, osteoporosis and osteopenia, occurs in persons 
with HIV regardless of their use of ART. Yet ART, especially protease inhibitors, seems 
to exacerbate the problem (Moore et al., 2001; Tebas et al., 2000). Several studies found 
bone mineral density (BMD) lower in older adults with HIV. Amiel et al. (2004), Calmy 
et al. (2009), and Önen, Overton et al., (2010) found lower BMD in older adults with 
HIV. Calmy et al. attributed bone loss primarily to the use of protease inhibitors, where 
Amiel et al. and Önen, Overton et al. identified HIV infection itself as the primary cause 
of decreased BMD. Irrespective of the cause, bone fractures, especially in older patients, 
decrease the ability to perform ADLs, including medication management. As this 
population ages, problems related to bone disease increase as well. Longer time living 
with an HIV infection, and longer time on ART are both associated with decreased BMD 
and fractures.  
Cancers 
Before ART, untreated HIV infection was associated with increased risk for 
Kaposi’s sarcoma and non-Hodgkins lymphoma (Biggar, Chaturvedi, Goedert, & Engels, 
2007; Engels et al., 2006). More recently there has been an increase in rates of non-AIDS 
related cancers (Deeks & Phillips, 2009; Hessol et al., 2007; Patel et al., 2008; Shiels, 
Cole, Kirk, & Poole, 2009). Long-term immunosuppression is associated with increased 
cancer risk (Bower et al. 2003; Monforte et al., 2008; Grulich, Leeuwen, Falster, & 
Vajdic, 2007).  
Frain, Judy, 2013, UMSL,   44 
 
 Smoking is a modifiable risk factor for cancer. As mentioned earlier, smoking 
rates are increased in persons living with HIV. This contributes to the high incidence of 
some cancers, including lung cancer, in this population (Bazoes, Bower, & Powles, 2008; 
Chaturvedi et al., 2007). Studies by Bazoes et al. (2008) and Chaturvedi et al. (2007) 
acknowledge the role of smoking in increased lung cancer rates but determined that other 
factors, as yet unidentified, may play a role, since smoking rates alone do not account for 
the disparity in cancer rates between persons living with HIV and those without HIV. 
 The exact role HIV plays in cancer risk remains inconclusive. Research to 
understand the cancer-causing mechanism of HIV and immunosuppression is ongoing. 
Another unexplained influence on cancer-causing mechanisms is long-term use of ART.  
Cancer treatments suppress the immune system and managing these two diseases together 
becomes a complicated clinical problem.   
Peripheral Neuropathy 
Peripheral neuropathy remains the most common neurological complication of 
HIV in the ART era. Ironically there are more instances of ART-induced peripheral 
neuropathy than disease-induced peripheral neuropathy (Sacktor, 2002; Schifitto et al., 
2002). Studies indicate the risk of peripheral nerve disorders increase with low CD4 
counts, high plasma viral loads, and increased age (Fellay et al., 2001; Simpson, et al. 
2002; So, Holtzman, Abrams, & Olney, 1988). Lichtenstein, et al. (2005), Simpson, 
Brown and Tobias (2008), and Watters et al. (2004) found an association with aging and 
peripheral neuropathy, noting that an increase in the number of comorbidities contributed 
to the increase in peripheral neuropathy in older adults.  
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 The emergence of new medications to treat HIV has decreased instances of 
peripheral neuropathy (Schifitto et al., 2002). Yet peripheral neuropathy continues to 
affect a significant portion of adults living with HIV, especially long-term survivors. 
Most began treatment with medications that caused neuropathy and were the only 
treatment option available (Lichtenstein et al., 2005). The pain and disability associated 
with peripheral neuropathy results in high treatment costs, decreased productivity, 
decreased quality of life, and a decrease in the ability to perform ADLs, including 
medication management (Berg et al., 2009; Nicholas, et al., 2007; Simpson et al., 2008).  
Frailty 
A recent area of concern for older adults living with HIV is early-onset frailty. 
Frailty is a syndrome involving loss of muscle mass, weight loss, decreased energy, and 
low physical activity levels (Henry, 2009). Desquilbet et al. (2007) found HIV infection 
strongly associated with frailty. In a study by Önen et al. (2009) frailty was associated 
with more comorbidities and higher hospitalization rates. Research by Ruiz and Cefalu 
(2011) found 30% of community dwelling HIV patients over age 60 were frail, while less 
than 20% of community dwelling adults over age 65 without HIV. Desquilbet et al. 
(2009; 2011) suggested that a compromised immune system was independently 
associated with frailty, and frailty was predictive of mortality. Frailty complicates a 
person’s ability to perform ADLs, including medication management.  
Neurocognitive Disoders  
In studies by Barrclay et al. (2007) and Hinkin et al. (2004) older age was 
associated with successful medication management except when older age was 
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accompanied by cognitive decline. In the Barclay et al. study, neurocognitive functioning 
was the best predictor of medication management in adults with HIV over the age of 50.  
Neurocognitive disorders are common in adults living with HIV. These HIV-
associated neurocognitive disorders are found in about 30% of adults with asymptomatic 
HIV, and 50% of adults with AIDS (Woods, Moore, Weber, & Grant, 2009). Older adults 
with HIV suffer neurocognitive disorders at a higher rate than their younger counterparts 
for several reasons including longer use of ART and poorer immune reconstitution 
(Cherner et al. 2004). These HIV-associated neurocognitive disorders are different from 
the neurocognitive decline associated with normal aging (Clifford et al., 2009).  
  Valcour, Shikuma, Shiramizu et al. (2004) found older adults with HIV were 1.3 
to 8 times more likely to have dementia than were younger adults with HIV, unrelated to 
the duration of their HIV infection. Not only do the rates of neurocognitive disorders 
increase as HIV disease progresses but the severity of the disorders increase as well. 
Heaton et al. (2010) found this increase in severity remained even after immune recovery 
was achieved, suggesting that starting ART earlier may reduce the rate of neurocognitive 
disorders.  
 Although ART has improved neurocognitive functioning, milder forms of HIV-
associated neurocognitive disorders are present even in those persons with an 
undetectable viral load (Tozzi, Balestra, Libertone, & Antinori, 2010). Studies by 
Anthony, Ramage, Carnie, Simmonds, and Bell (2005), Price and Spudich (2008), and 
Clifford (2008) found significant, ongoing neuroinflammation in patients treated with 
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ART, warning of the increased probability of future neurocognitive problems for persons 
living with HIV long term.  
 In a new area of research, Ances et al. (2010) and Paul et al. (2008) used MRIs to 
detect changes related to cognitive decline, and found that HIV infection and aging 
independently affected brain functional demands. This line of research could lead to a 
noninvasive biomarker of HIV infection in the brain. Currently lumbar punctures, often 
painful and with risk of injury to the patient, are the only method available in determining 
the amount of HIV virus in the brain (Clifford, 2008). 
 Medication management is a vital component of combating HIV disease but is 
more difficult for persons with neurological impairment (Gorman, Foley, Ettenhofer, 
Hinkin, & van Gorp, 2009; Selnes, 2002; Woods et al., 2008). Increased fatigue and a 
decrease in independent functioning, both factors that affect medication management, 
have been found to be associated with neurological impairment (Waldrop-Valverde, 
Jones, Gould, Kumar, & Ownby, 2010). 
 Research is mounting that neurocognitive decline begins earlier in persons living 
with HIV (Ances et al., 2010; Barclay et al., 2007). There is strong evidence that this 
decline affects medication management and may be the best predictor of medication 
management for older adults living with HIV (Barclay et al., 2007). Interestingly, a study 
by Ettenhofer et al. (2009), agreed that cognitive decline was a strong predictor of poor 
medication management. Ettenhofer hypothesized that it was suboptimal medication 
management when persons were younger that contributed to the neurocognitive decline 
later found in older adults.  
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Psychosocial Aspects of Aging with HIV 
Despite the profound medical effect aging has on older adults living with HIV, 
many living with the disease would consider the non-medical, psychosocial effects to 
take a greater toll (Emlet & Farkas, 2001; Sayles, Wong, Kinsler, Martins, & 
Cunningham, 2009). Older adults living with HIV experience many of the same stressors 
as younger adults with the disease but are also faced with challenges unique to an aging 
population (Emlet, 2006b). Feelings of stigmatization and isolation are issues older adults 
may experience to a greater degree than younger persons. A study by Emlet (2006b) 
found nearly every person over 50 years of age experienced HIV stigma, and over two-
thirds experienced both ageism and HIV stigma.  
Herek (1999) defines HIV stigma as prejudice and discrimination directed at 
persons who have, or are perceived to have, HIV or AIDS. Ageism is defined as a 
negative attitude toward persons based on the idea that aging makes a person 
“unattractive, unintelligent, asexual, unemployable, and mentally incompetent” (Atchley 
& Barusch, 2004, p. 439). Older adults with HIV face double jeopardy in having to deal 
with both HIV stigma and ageism, effecting both physical and mental health.  
  A survey by the Kaiser Family Foundation (2011) commissioned as the 
HIV/AIDS epidemic marked 30 years offered some discouraging results. Although 
stigmatizing attitudes have decreased, an alarming number of people still acknowledge 
holding negative views of persons living with HIV. Forty-five percent do not want 
someone with HIV preparing their food, 29% would not want their children to have a 
teacher with HIV, and 29% still think if a person contracts HIV it is their own fault 
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(Kaiser Family Foundation, 2011). While these percentages are lower than in the early 
years of the epidemic, the numbers serve as a discouraging reminder of the prejudices 
and stigma persons living with HIV face daily. 
Delayed and decreased access into care has been attributed to HIV stigma 
(Heckman, Heckman, Kochman, Sikkema, Suhr, & Goodkin, 2002; & Sayles, Wong, 
Kinsler, Martins, & Cunningham, 2009). Less access to care leads to persons presenting 
with advanced HIV disease, which complicates care and treatment. (Heckman, Heckman, 
Kochman, Sikkema, Suhr, & Goodkin, 2002). Nurses and other healthcare providers are 
perceived to stigmatize persons with HIV according to a study by Kinsler, Wong, Sayles, 
Davis, and Cunningham (2007), where 25% of participants reported feeling stigmatized 
during a health care visit.  
Black men may be more strongly affected by HIV stigma than any other group. 
Williams, Wyatt, Resell, Peterson and O’Brien (2004) found Black men perceived stigma 
as more prevalent and strongly associated with homophobia in the Black community. 
This stigma caused men who had sex with men to self-identify as heterosexual. Many of 
the men refusing the label of gay reported having sex with women to maintain their 
heterosexual identity. This activity increases the risk of HIV infection for Black women 
and is a contributing factor to the high HIV rates found in Black women (Williams et al., 
2004).  
Fear of rejection and HIV stigma can prevent people from disclosing their illness 
to friends and family (Brennan, Emlet, & Eady, 2011). This can result in increased social 
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isolation and loneliness, both associated with poorer medication management (Emlet, 
2006a; Vanable, Carey, Blair, & Littlewood, 2006).  
Several studies have found a strong correlation between stigma and depression 
(Emlet, 2007; Grov, Golub, Parsons, Brennan, & Karpiak, 2010; Heckman, Kochman, & 
Sikkema, 2002), and depression is strongly associated with poor medication management 
(Holstad, Foster, DiIorio, McCarty, & Teplinskiy, 2010; Willard, 2006). Levy-Dweck 
(2005) cautions the double stigma of HIV and ageism could result in lower quality of 
social services and possible denial into long-term care facilities.  
Depression 
Depression is the most common and heavily studied psychological problem in 
persons living with HIV. There are many reasons for depression in older adults living 
with HIV in addition to the burden of living with a chronic illness. Chief among the 
reasons is the stigma and isolation associated with HIV (Emlet, 2006b). Stigma is often 
cited by patients as a deterrent to sharing their HIV diagnosis, leading to isolation and a 
lack of social support, which in turn leads to higher rates of depression and cognitive 
decline (Cornwell & Waite, 2009; Emlet, 2007). 
Adults living with HIV have much higher rates of depression than the general 
public (Voss, Portillo, Holzemer, & Dodd, 2007). In adults with HIV, depression rates 
ranged from 50 to nearly 70% (Treisman, Angelino, & Hutton, 2001; Voss, 2007; 
Vosvick, Martin, Smith, & Jenkins, 2010). Depression in persons with HIV has been 
associated with poor medication management, higher levels of stress, and increased 
morbidity and mortality (Knowlton, Curry, Hua, & Wissow, 2009; Springer, Chen, & 
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Altice, 2009). Several studies on HIV and depression have found that older adults with 
HIV exhibit higher rates of depression than their younger counterparts (Grov, Golub, 
Parsons, Brennan, & Karpiak, 2010; Heckman & Heckman et al., 2002; Justice et al., 
2004; Karpiak & Shippy, 2006; Shippy & Karpiak, 2005a).  
Depression affects health-related quality of life (HRQOL).  Studies by 
Cunningham, Crystal, Bozzette, and Hays (2004) and Murri et al. (2003) found that 
HRQOL was a strong predictor of survival independent of standard medical measures 
such as CD4 count and stage of HIV infection. Overall it appears there is an association 
between older age and lower HRQOL (Hudson, Kirksey, & Holzemer, 2004; Nokes et 
al., 2011). The majority of the studies, including those by Hays et al. (2000), Jia, Uphold, 
Zheng et al. (2007), Mowad (2004), and Nokes et al. (2000) determined that decreased 
social support, depression, and other comorbidities, all of which are more prevalent in 
older adults living with HIV, were reasons for the lower HRQOL in the older cohorts.  
Depression is also associated with disease progression and shortened survival 
time (Farinpour et al., 2003). Pence, Miller, Gaynes, and Eron (2007) found depression 
associated with a slower rate of virologic suppression, while Mugavero et al. (2007) 
found an association between depression and opportunistic infections. Slow virologic 
response is of special concern for older adults with HIV, since they have a less robust 
virologic response to treatment than younger adults, and are often diagnosed later in the 
disease process, leading to longer periods of immunosuppression (Silverberg, Leyden et 
al., 2007; Kirk & Goetz, 2009). 
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In studies looking at the association between depression and medication 
management, Holzemer et al. (1999), Gonzalez et al., (2004), Paterson et al. (2000), and 
Horberg et al. (2008) found persons with depressive symptoms more likely to exhibit 
poor medication management. Similarly, in studies focused on older adults, Cruess, 
Kalichman, Amaral, Swetzes, Cherry and Kalichman (2012) and Wagner et al., (2011) 
found an increase in depressive symptoms was associated with poor medication 
management. Studies report that antidepressant medication is efficacious in treating 
depression in older adults living with HIV (Rabkin, McElhiney, Rabkin, McGrath, & 
Ferrando, 2006). Furthermore, when depression is treated effectively, medication 
management improves (Dalessandro et al., 2007; Holzemer et al., 1999; & Horberg et al., 
2008).  
Unfortunately depression often goes undiagnosed in older adults living with HIV 
(Voss et al., 2007). Older adults were less likely to report depressive symptoms and 
depressed older adults were less likely to receive treatment for their depression than were 
younger adults (Voss et al., 2007; Zanjani, Saboe, & Oslin, 2007). When left untreated 
depressive symptoms can lead to poorer medication management and poorer health 
outcomes (Asch et al., 2003). 
Isolation and Social Support 
Studies find that older adults with HIV live alone at almost twice the rate of older 
adults in the general population, and they also have smaller support networks (Emlet, 
2006a; Karpiak & Shippy, 2006; Poindexter & Shippy, 2008; Shippy & Karpiak, 2005a). 
Isolation has been associated with increased morbidity and mortality, high rates of 
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depression and cognitive decline (Grov, Golub, Parsons, Brennan, & Karpiak, 2010). 
Cornwell and Waite (2009) found isolation and social disconnectedness were 
independently associated with decreased physical and mental health. Studies by Esterling, 
Kiecolt-Glaser, and Glaser (1996) and Lutgendorf et al. (2005) found an association 
between social support and immune function, asserting that social support is an important 
component of battling HIV disease. 
  Studies by Nokes et al. (2000), Poindexter and Shippy (2008), Schrimshaw and 
Siegel (2003), and Shippy and Karpiak (2005a) found older adults with HIV perceived a 
lack of social support. This perception resulted in a significantly smaller circle of persons 
in whom they felt they could confide about their illness (Emlet, Tozay, & Raveis, 2011; 
Karpiak, Shippy, & Cantor, 2006). The lack of social support for older adults with HIV 
was due in part to self-isolation, choosing not to disclose their HIV status to family or 
friends because of the fear of stigma (Shippy & Karpaik, 2005a). Shippy and Karpiak 
(2005b) found older adults with HIV relied on formal care networks instead of traditional 
informal networks that older adults with other chronic diseases frequently use. Research 
suggests that these informal networks often formed around other persons with HIV or 
other chronic diseases. The result was these informal networks were unable to provide 
needed support because members of the network were debilitated by their own disease 
and were unable to provide support. 
 Many studies have found a positive association between social support and 
medication management (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000; Gonzalez et 
al. 2004; Holstad, Pace, De, & Ura, 2006; Power et al. 2003; Simoni, Frick, Lockhart, & 
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Liebovitz, 2002; Stirratt, et al., 2006). These studies did not differentiate between support 
from a partner and other support. However in a study that did make the distinction 
between partner and other support, Power et al. (2003) found that only social support 
from a partner was strongly associated with medication management. Support from 
friends and family was not significantly related to medication management. This is 
important because older adults living with HIV are less likely to have a life partner. 
 Older adults with HIV not only have smaller support networks but they also lack 
the formal support used by older adults with other chronic diseases (Emlet & Poindexter, 
2004). In examining formal support networks, Emlet and Poindexter (2004) argue for the 
integration of gerontological services and HIV services in order to provide holistic care 
for this emerging demographic. Emlet and Poindexter cite examples of older adults with 
HIV feeling unwelcome at AIDS Service Organizations (ASOs) that were judged to be 
geared to younger adults. These older adults felt just as uncomfortable in the aging care 
network, where staff was often unfamiliar and sometimes uncomfortable with the needs 
of older adults with HIV. 
Theoretical Framework 
Social Cognitive Theory provides a framework for understanding, predicting, and 
affecting human behavior. This theory was developed by Bandura (1977) to explain how 
personal and environmental factors interact to affect human behavior. According to 
Bandura (1997) it is the combined influences of personal and environmental factors that 
influence a person’s thoughts and ultimately leads to behavior. A model of social 
cognitive theory developed for this study is depicted in Figure 1.  
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In this theoretical model, the interaction between personal and environmental 
factors influences a person’s thoughts and eventually their behaviors. Interaction between 
the person and the environment involve the factors of cognition, depression and self-
efficacy and how they are continually modified by the environment. The environment, 
including friends, family, healthcare providers and socio-economic factors like wealth 
and stable housing is modified by personal factors of cognition, depression and self-
efficacy. Both personal and environmental factors require cognitive processing to affect 
behavior. In this model medication management is being studied. In a reciprocal loop 
effective medication management in turn affects personal and environmental factors. 
Medication management is a complicated set of behaviors. In order to be 
successful in HIV medication management a person must have knowledge and skills to 
perform the tasks, but a person must have the belief that they can continue to successfully 
complete these tasks over a long period of time. The person must then be able to 
understand the complexity of medication management in order to be successful in 
medication management.  
High self-efficacy along with cognitive ability and low level of depression can 
overcome environmental barriers in order to effectively manage medications (Bandura, 
1989). These determinants are constantly interacting. Self-efficacy is a major construct of 
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Figure 1: Social Cognitive Theory Model 
 
 
Self-efficacy is described as a person’s confidence in their ability to perform a 
particular behavior (Bandura, 1997). According to Bandura (1989), self-efficacy beliefs 
are what determine a person’s level of motivation and these beliefs influence the effort a 
person exerts on a particular task. When a person has a strong belief in their ability to 
perform a task, they will endure in spite of difficulties they encounter. However, a person 
who doubts their ability to successfully perform a task limits their effort or may 
eventually abort the attempt altogether when confronted with adversity (Bandura, 1989).  
According to Social Cognitive Theory, perceived self-efficacy and outcome 
expectancies are important factors that influence behavior (Bandura, 2004). A person will 
not set a goal of taking their medications correctly 100% of the time if they do not 
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believe that doing so will result in better health. Antiretroviral therapy is difficult to 
tolerate. Persons may abandon ART if they do not have a strong belief in the efficacy of 
the medications that make up the therapy. Persons starting ART for the first time or 
persons changing their ART regimen may experience diarrhea, nausea, vomiting, fatigue 
and rashes.  These, along with other debilitating side effects of the medications, can act as 
barriers to successfully completing the task of medication management. Persevering 
through the difficult initial weeks on therapy is made easier, and better tolerated if a 
person understands that the downside of short-term side-effects is outweighed by 
successfully achieving the long-term goal of HIV viral suppression.  
Medication management is a skill that may become more difficult for older adults 
with HIV because of obstacles that impede the successful mastery of this task. Increased 
pill burden, depression, and cognitive decline are personal factors that can create self-
doubt and decrease self-efficacy in one’s ability to successfully master the skill of 
medication management. This self-doubt may discourage a person from attaining and 
maintaining the high level of medication management necessary to prevent virologic 
failure, which then can introduce new obstacles to successfully managing their illness. 




The primary aim of this research was to examine if medication management was 
different for older adults living with Human Immunodeficiency Virus (HIV) compared to 
younger adults living with HIV. The secondary aim was to examine the relationship 
between age, personal factors (cognitive ability, depression, and self-efficacy) and 
medication management among participants. The two study aims were achieved through 
the following research questions. 
Question 1: Is there a difference in the medication management ability between older 
and younger adults living with HIV? 
Question 2: Are there differences in cognitive ability, depression, or self-efficacy 
between older and younger adults living with HIV? 
Question 3: What are the associations between personal factors (cognitive ability, 
depression, and self-efficacy) and medication management among older and younger 
adults living with HIV, respectively?  
Question 4: Which personal factors (cognitive ability, depression, and self-efficacy) are 
the best predictors of medication management among adults living with HIV, controlling 
for age as a covariate?  
Methodology 
Research Design 
This research utilized a descriptive-correlational, cross-sectional design in 
examining whether there was a difference in medication management between older and 
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younger adults living with HIV. The influence of age was examined in the associations 
between personal factors (cognitive ability, depression, and self-efficacy) and medication 
management. The factors (cognitive ability, depression and self-efficacy) have been 
observed in practice and previously studied in persons living with HIV. However, what 
was unknown is their influence on medication management among the older HIV 
population. 
A descriptive-correlational cross-sectional design allows the researcher to 
describe selected variables and study associations between groups (Taylor & Kermode, 
2006). It was chosen for this study to compare the characteristics of groups according to 
selected variables. Variables for this study were selected on the basis of previous studies 
where cognitive decline, depression and self-efficacy have an effect on medication 
management. More importantly these factors are found at higher rates in older adults with 
HIV than in younger adults with HIV. This study adds to nursing knowledge of older 
adults living with HIV by examining how this population can manage their medication 
regimens, and what clinical variables predict the ability to manage their medications. 
Instruments 
 Participants completed four existing standardized instruments along with a 
Demographic Form. As shown in Table 2, the four standardized instruments were: the 
Center for Epidemiological Studies Depression Scale (CES-D), the Medication 
Management Task-Revised (MMT-R), the Montreal Cognitive Assessment (MoCA), and 
the Self-Efficacy for Chronic Disease Scale (SE-CDS). The CES-D was used to measure 
depression (Appendix A). The MMT-R was used to measure medication management 
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(Appendix B). The MoCA was used to measure cognitive ability (Appendix C). The SE-
CDS was used to measure self-efficacy (Appendix D). All four instruments have been 
used in previous studies of persons living with HIV. These particular instruments were 
chosen for this study not only because of their reliability but their brevity makes them 
useful in clinical settings. Another reason for choosing these instruments is that they 
would not be overly burdensome on patients, an important consideration when choosing 
research instruments. The Demographic Form collected descriptive data about the 
participants. (Appendix E). 
Table 2. 
 Instruments 





CES-D Depression 20 Total Score 
of 0-60 
5 minutes 0.90 
MMT-R Medication 
Management 
10 Total Score 
of 0-16 
10 minutes 0.72 
MoCA Cognitive 
Ability 
30 Total Score 
of 0-30 




Self-efficacy 6 Total Score 
of 1-10 





  10 minutes  
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The researcher administered the MoCA and MMT-R. The CES-D and SE-CDS 
instruments were self-administered and were completed by the study participants. 
Information collected on the Demographic Form was collected from study participants 
and from information gathered from medical records. 
The Center for Epidemiological Studies Depression Scale: CES-D 
The CES-D (Radloff, 1977) is a 20-item self-administered depression 
questionnaire. Total scores can range from 0 to 60. The instrument asks participants to 
consider the past 7 days when answering the questions. Scoring for each item is on a 4-
point scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time). 
Scores on items 4, 8, 12, and 16 are reversed. A higher score indicates a higher level of 
distress. A score >16 indicates a clinically significant level of distress. Less than 20% of 
the general population would be expected to score in this range. A score > 23 indicates 
major depressive symptoms. 
The CES-D has been used in many large-scale HIV/AIDS research trials. 
Reliability and validity have been well-established. Chronbach’s Alpha is 0.94 (Radloff, 
1977).  
An example of a question is: “I was bothered by things that usually don’t bother 
me” 
Four of the questions have reversed scoring. 
An example of a question scored in reverse is: “I felt hopeful about the future” 
Study participants who score greater than 16 on the CES-D were referred to their 
HIV healthcare provider for follow-up. 




The Medication Management Task-Revised: (MMT-R) 
The MMT-Revised is a performance test designed to assess medication 
management skills. The MMT-R was developed by Heaton et al. (2004) taking the most 
valid and reliable items from their original medication management test developed by 
Albert et al. (1999). Medication management has been defined as “the cognitive and 
functional ability to self-administer a medication regimen as it has been described” 
(Madigan, Farris, Wiens, & Johnson, 2003, p. 333). 
The MMT-R is a 10-item questionnaire consisting of two components. The 
questionnaire is administered by the researcher. The pill-dispensing component measures 
the participant’s ability to dispense a day’s dosage of medications. The medication 
inference component requires the participant to answer questions about the medications, 
such as how long a medication prescription will last, and how many times a day a 
particular medication must be taken. A higher score indicates better medication 
management. The final question consists of 10 parts that focus on participants’ own 
medications. Examples of the questions are “how many different medications do you take 
on a daily basis?” and “how many pills do you take on a daily basis?”  
 The original MMT reliability ranged from .63 to .74 for the medication inference 
component, and .78 to .84 for the pill-dispensing component (Albert et al., 1999). In 
another study using the MMT, it was found that cognitive deficit in persons with HIV 
was associated with greater risk of error on the MMT (Albert et al., 2003). Albert et al. 
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also found beliefs about medication efficacy affected scores on the MMT. The MMT-R is 
a revised version of the original MMT, using only the items deemed most reliable and 
valid from the pilot work (Heaton et al, 2004). This revised version retains both the pill-
dispensing component and the medication inference component found in the original 
version; however, the total number of questions has been decreased. Completion time has 
also been shortened to 10-15 minutes, from the 15-25 minute completion time of the 
original version. The overall reliability of the MMT-R was 0.72 in a study of 193 persons 
living with HIV (Heaton, 2004). 
 Items from the medication inference component include questions concerning 
dosage information, special instructions such as take with food, take on an empty 
stomach, or how long medication prescriptions will last. The pill dispensing component 
includes questions about the number of medications taken on a daily basis, the total 
number of pills and supplements taken daily, and questions about medication aids such as 
pill organizer and timing devices. 
The Montreal Cognitive Assessment: (MoCA) 
The MoCA is a 30-item assessment tool used as a screening instrument for mild 
cognitive dysfunction. It was developed by a group of Canadian researchers to assist in 
detecting mild cognitive decline in the clinical setting (Nasreddine et al., 2005). The test 
is administered by the researcher. It is designed as a quick screening tool to assess mild 
cognitive dysfunction, taking only about 10 minutes to complete. The MoCA assesses 
different cognitive domains: attention, concentration, executive function, memory, 
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language, visioconstructional skills, conceptual thinking, calculations, and orientation. 
The total possible score is 30, and a score of 26 or above is considered normal. 
 The MoCA was first tested in a study that included 94 patients meeting mild 
cognitive decline criteria, 93 patients with mild Alzheimer’s disease, and 90 healthy 
elderly controls. It was shown to have sensitivity and specificity (Nasreddine et al., 
2005). 
 Since its initial validation, the MoCA has been used to determine mild cognitive 
decline in many studies. Recently the MoCA has been used in studies of persons living 
with HIV (Koski et al., 2011; Musso et al., 2011). In a study of 69 patients with HIV, the 
MoCA was found to be useful in screening for HIV dementia. However, a slightly lower 
cutoff of < 24 was proposed (Musso et al., 2011). Koski et al. found the MoCA effective 
in the geriatric and HIV populations.  The MoCA was chosen for this study because it is a 
quick screening tool that can easily be included in a healthcare visit with immediate 
results that could alert the healthcare team of mild cognitive impairment, or cognitive 
changes that may otherwise be missed. 
The Self-Efficacy for Chronic Disease Scale: (SE-CDS) 
This scale was developed by the Stanford Patient Education Research Center. The 
Center has nearly 20 years of work developing, adapting, and testing self-administered 
scales. Self-efficacy is an integral component of Social Cognitive Theory, and has been 
shown to be a predictor of the adoption of healthy behaviors, including medication 
management (Bandura, 1997). The SE-CDS is a quick screening tool that measures self-
efficacy in persons living with chronic diseases. It has been shown to be reliable and 
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consistent. When tested with 605 persons with chronic disease, internal consistency and 
reliability was found to be 0.91. The 6 items had an observed range of 1-10, with a mean 
of 5.17 and a standard deviation of 2.22 (Lorig, Sobel, Ritter et al., 2001). This SE-CDS 
uses a Likert-like scale with answers ranging from 1 (not at all confident) to 10 (totally 
confident).  
This scale was designed specifically for self-efficacy in managing chronic 
disease. An example of a question on the scale is: “How confident are you that you can 
keep the emotional distress caused by your disease from interfering with the things you 
want to do?”  Total scores are divided by the number of questions (6), resulting in total 
scores between one and 10, with higher scores indicating an increased ability to manage 
chronic disease. 
 This scale was chosen for this research study as it is minimally burdensome for 
patients, can provide a quick gauge of a patient’s self-efficacy in a clinical setting, and 
has been shown to be reliable in past research.  
Demographic Form 
 The Demographic Form will collect data from the participant and from medical 
records. The information collected includes:  
• Participant’s name, date of birth, study visit date and assigned study number 
• Study arm (Age 50 and older or Under age 50) 
• Current and past alcohol, tobacco, and drug use  
• Nadir and current CD4 counts, current HIV viral load 
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• Year of HIV diagnosis, date of HIV confirmation used for study, time on HIV 
medications 
• ART and other medications 
• Diagnoses (other than HIV) 
• Race, gender, Hispanic ethnicity 
• Years of education completed 
• Test scores from completed study instruments 
Inclusion and Exclusion Criteria 
 This study used a convenience sample of adult men and women living with HIV 
and currently taking antiretroviral medications. The inclusion criteria for this study are 
listed in Table 3. 
The inclusion criteria for study participation included men and women living with 
HIV who were at least 18 years of age. The HIV infection was determined by a licensed 
ELISA test and a confirmatory Western Blot documented in the medical record, or two 
documented detectable HIV viral loads at any time prior to entering the study. 
Participants must have been on an antiretroviral regimen for at least 16 consecutive 
weeks prior to entering the study. Sixteen weeks on ART was chosen as the minimum 
time to be on ART because it may take 16 weeks to determine the effectiveness of the 
medication. Participants in this study must have had the ability to read and speak English. 
This requirement was established because the instruments used in this study were all in 
English, and their reliability has been determined using an English version of the 
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instrument. Lastly, participants all provided written informed consent of their 
participation in this study. 
Table 3. 
 Inclusion Criteria 
1 Men or Women at Least 18 years of age 
2 HIV infection as documented by a licensed ELISA test and confirmed by a 
Western Blot or alternatively two documented detectable HIV viral loads at any 
time prior to study entry 
3 Receipt of antiretroviral regimen for at least 16 consecutive weeks prior to 
study entry 
4 Ability to read and speak English 
5 Ability and willingness of study participant to provide written informed consent 
 
The exclusion criteria for study participation include persons less than 18 years of 
age. This age was chosen as 18 is the age commonly used in adult HIV research. Persons 
were excluded from this study if they did not have a documented HIV infection. 
Documentation required a positive ELISA and confirmatory Western Blot or two 
detectable HIV viral loads prior to entry into the study. Persons who had not been on 
antiretroviral therapy for at least 16 weeks were excluded from the study. Persons who 
did not read or speak English were not enrolled in this study as the survey instruments 
used are all written in English, and their reliability has been determined using an English 
version of the instrument. Lastly, participants were not enrolled in this study if they 
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refused to provide written informed consent. The exclusion criteria for this study can be 
found in Table 4. 
Table 4.   
Exclusion Criteria 
1 Less than 18 years of age 
2 No documentation of HIV infection 
3 Less than 16 consecutive weeks on HIV medications 
4 Inability to read and understand English 
5 Unable or unwilling to give written informed consent 
 
There were two groups in this study. Group 1 was comprised of participants 50 years 
of age and older. Group 2 was comprised of participants between the ages of 18 and 49 
years of age. A goal of recruiting 25% women into each group was established in order to 
resemble national percentages of women living with HIV. 
Sample Size 
To determine sample size for this study, alpha was set at .05 and beta at .80, and 
calculated on a two-tailed t-test to detect a moderate effect size of medication 
management between the two groups (Faul, Erdfelder, Lang, & Buchner, 2007). Using 
the G-power statistical program, a total of 128 participants were required to be enrolled in 
this study. This number is in line with other rules for calculating sample size (Field, 
2005). Therefore, rounding up required enrollment of 130 participants. There were 65 
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participants in the group of adults age 50 and older and 65 participants in the group of 
adults age 18 to 49.  
Recruitment 
Participants for this study were recruited from the Infectious Diseases Clinic and 
the AIDS Clinical Trials Unit (ACTU) at Washington University School of Medicine. 
The researcher reviewed the clinic and ACTU schedules each day to identify persons 
potentially eligible for the study. This initial identification was limited to age and HIV 
status. A research assistant employed by the ACTU was informed of persons potentially 
eligible for the study. She approached these persons while they were at their healthcare 
appointment and inquired about their participating in a study designed to examine 
medication management in persons living with HIV. When a potential volunteer 
expressed interest in participating they were taken by the recruiter to a private room 
where they were provided information about the study and given a copy of the informed 
consent document for the study. When the researcher was available she met with the 
person at that time and answered any questions they had related to the study 
requirements. If the potential volunteer and the researcher were both available, the 
appointment took place at that time. 
If the researcher was not available at that time the recruiter notified the researcher 
of the potential volunteer’s interest in the study, and the researcher contacted the 
volunteer to answer any questions they had regarding the study. If the potential volunteer 
agreed to participate in the study an appointment was scheduled at a time convenient to 
both the researcher and the participant. Recruitment procedures are outlined in Table 5. 
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Table 5. 
 Recruitment Procedures 
1 The researcher will look at the clinic and ACTU appointment calendars for the 
day and with the use of medical records determine which clients may be eligible 
for the study.  
2 A research assistant, who is employed as a recruiter for the ACTU will 
approach clients initially considered to be eligible who are at the Infectious 
Disease clinic or the ACTU for an appointment and ask them if they would be 
interested in participating in a study designed to examine medication 
management in persons living with HIV. 
3 If a person expresses interest in participating, they will be ushered into a private 
room where they will be provided with more information about the study. 
4 The study will be explained in greater detail, and the volunteer will be provided 
an informed consent document to read. The researcher will be available to 
answer any questions at this time. 
5 If the potential participant and researcher are available, enrollment into the 
study can take place at this time. 
6 A potential participant may also choose to schedule a study visit at a future time 
convenient to both the participant and the researcher.  
7 At the study appointment, the participant along with the researcher will 
complete the informed consent process, the researcher will answer any 
questions the participant may have, and the participant will be given a copy of 
the informed consent document. 
8 The participant will be able to complete the study in a single visit of about one 
hour.  
9 Upon completion of the study, the participant will be given $10 cash as 
remuneration for their time. 




This study took place at the ACTU at Washington University School of Medicine, 
located in the city of St. Louis, Missouri. The ACTU at Washington University is the 
major research center for conducting HIV/AIDS research in the St. Louis area. 
Established in 1987, the unit has operated continuously since that time enrolling 
volunteers in clinical trials. The trials are predominantly therapeutic but not exclusively 
so. The majority of participants have been enrolled in studies funded by the National 
Institute of Allergy and Infectious Diseases (NIAID). In addition Washington University 
and industry-sponsored studies are offered to participants at this site. The ACTU 
currently follows more than 800 participants in clinical trials. The ACTU is a referral 
clinic and draws participants from throughout the states of Missouri and Illinois. The 
ACTU provides ample parking for volunteers and is conveniently located adjacent to the 
Metrolink rail line and bus lines.  
 Located in the same building as the ACTU but in a separate physical space is the 
Washington University Infectious Disease outpatient clinic. The Infectious Disease clinic 
is the primary recruitment point for the ACTU. The clinic provides care to well over 
1,600 HIV infected individuals. This is a major clinic for persons newly diagnosed with 
HIV/AIDS in the area, seeing 3-4 new patients per week. Patients followed in the 
Infectious Disease practice are regularly referred for participation in clinical trials. The 
researcher has worked for eleven years in HIV clinical research, the last seven of which 
have been at the ACTU as a clinical research nurse. The researcher has been trained and 
certified in neurocognitive testing. The researcher has been trained in the use of all the 
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study instruments. The researcher has also worked extensively in improving medication 
management with research participants new to and experienced with HIV medications. 
Data Collection Procedures 
Written informed consent was obtained from all participants prior to completing 
any study-related questionnaires. All study procedures took place in a quiet, private room 
with adequate lighting and a flat writing surface. After obtaining informed consent, the 
researcher, together with the participant, completed the Demographic Form. The 
researcher then administered the MoCA followed by the MMT-R. After completion of 
these tests, participants completed the following self-administered questionnaires: CES-D 
and the SE-CDS. The researcher was available to assist the participants if they had 
questions about either of the instruments. The participants were given as much time as 
necessary to complete the questionnaires. The duration of the time it takes for a 
participant to complete the series of questionnaires was expected to be approximately one 
hour. These study visits ranged from about 45 to 75 minutes. Upon completion, the 
researcher checked the questionnaires for missing data before the participant left. If it was 
found that some questions had not been answered, the participant was asked if they were 
missed or intentionally left blank. Participants were not required to answer any questions 
they chose not to answer. At the conclusion of the study visit the participant was given 
$10 cash for their time and participation in the study. 
The researcher completed the Demographic Form using self-report from the 
participant along with accessing the medical records. The Demographic Form included 
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descriptive statistics along with other information. A copy of the Demographic Form can 
be found in Appendix E. 
 If the participant scored higher than 16 on the CES-D the researcher informed the 
participant of this score and advised them that this information would be provided to their 
HIV healthcare provider, as stated in the informed consent document. 
This study was run by the researcher. The researcher completed IRB training and 
worked in the past in a research capacity at the ACTU for over seven years. The 
researcher was trained on administration of all the screening tests included in this study, 
and was involved in several previous studies utilizing these and other similar screening 
tests. 
 Demographic information collected from the participants included age, gender, 
race, number of years since diagnosis, current CD4 and viral load (VL) counts. Each 
study packet was coded with a number for confidentiality purposes, and identifying 
information was not included in the coded data. It was estimated that the researcher 
would need about two hours to complete data collection for each participant. One hour 
was spent with the participant, and the second hour consisted of time spent recruiting 
participants and extracting data from medical records. 
Analysis and Data Management 
 Data was input and analyzed using the latest SPSS version available. Descriptive 
statistics were used to summarize the demographic characteristics of both groups. Data 
on current and historical use of tobacco, drugs, and alcohol was collected from the 
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Demographic Form. Current CD4 count and viral load was presented using descriptive 
statistics.  
Independent T-tests were used to compare the difference in continuous variables 
including age, pill burden, duration of HIV infection, time on Antiretroviral Therapy 
(ART), CD4 count and viral load between groups. Chi-square tests were used to examine 
the difference in discrete variables including gender at birth, current and historical use of 
tobacco, drugs, and alcohol.   
 The characteristics of study participants were reported as: age (mean years ± 
standard deviation [SD] ), male (%), ethnicity (%), CD4 count at study entry (cells/ml ± 
SD), viral load at entry (copies per ml ± SD), duration of HIV infection (mean years ± 
SD), time on ART (mean years ± SD),  and pill burden (number of pills per day ± SD). 
This information gathered on the Demographic Form was used to compare the two 
groups. 
 To answer research question one, a two-tailed t-test was used to analyze 
differences in medication management between older and younger adults with HIV. A 
two-tailed t-test was used because although it is expected there will be differences in 
medication management between the two groups, there was not enough data to determine 
the direction of the difference (Field, 2005).  
For research question two, two-tailed t-tests was used to analyze differences in 
cognitive ability, depression, and self-efficacy between older and younger participants. 
Effect size of cognitive ability, depression, and self-efficacy was determined through an 
analysis of mean difference scores between the older and younger groups on all overall 
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scores on each instrument using Cohen’s d (Cohen, 1988). Effect size quantifies the 
difference between the means of two groups, and is concerned with the strength of the 
relationship (Polit & Hungler, 1995).   
For research question three, Pearson correlation coefficients were computed for 
older and younger adults among the three independent variables; MoCA (cognition), 
CES-D (depression), and SE-CDS (self-efficacy), and the dependent variable, MMT-R 
(medication management).  
To answer research question four, multiple regressions were conducted to analyze 
the effects of cognitive ability, depression, and self-efficacy on medication management 
for the older and younger groups respectively. Regression analysis is used to make 
predictions about phenomena (Polit & Hungler, 1995). In this study multiple regressions 
were used to make predictions about medication management based on the effects of 
cognitive ability, depression and self-efficacy. Simultaneous regression, rather than step-
wise regression was used because there was not enough data to determine if any one of 
the variables would have a greater impact on medication management than the other 
variables. 
Data is stored on a hard drive and backed up on the server of the researcher’s 
computer. The computer is password protected. No identifying data is included in the 
stored computer data. Hard copies of the completed study visits are stored by the 
researcher in a locked file cabinet in a locked office.  
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Strengths and Limitations 
Strengths of this study include ready access to the population being studied and 
the strong research background of the researcher. The researcher is also aware of 
significant interest in research about the aging HIV community among current research 
participants and the local community advisory board at the Washington University 
ACTU. This group is comprised of community members affected by HIV. During 
monthly meetings held in a conference room within the ACTU building this group 
discusses current and future research studies. They have been vocal in their support for 
more studies directed at the aging HIV community. The community advisory board has 
been instrumental in disseminating information about HIV research studies of interest to 
the community.  
A limitation of this study is that all recruitment was done within a single 
geographical area, and only English speaking persons were enrolled, making the results 
of the study less generalizable. Another limitation is item burden; the use of multiple 
instruments may have placed a time and attention burden on participants 
Human Subjects Protection 
 This study has undergone full review by the Washington University Human 
Research Protection Office (HRPO) and the Institutional Review Board at the University 
of Missouri, St. Louis prior to implementation of the research project. The researcher met 
with and obtained signed informed consent from each participant in the study. Due to the 
confidential nature of this study, the consent form emphasized the privacy protections 
afforded participants in this study. Protected Health Information (PHI) has not, and will 
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not be disclosed to anyone by the researcher without written consent from the study 
participant. Participants were assigned an identification number (ID). Confidentiality was 
maintained by using ID numbers and not participant names. Only the investigator has 
access to code numbers that link information to a participant’s name. Records are kept in 
a locked, secured location accessible only to the researcher. Computer data is coded by 
ID number and does not contain identifying information. It is stored on a password-
protected computer. 
Time Frame 
 The HRPO approval took about three weeks. It was anticipated, based on 
experience from previous similarly designed studies, that enrollment goals could be met 
within four months of study initiation. In fact, the study was completely enrolled within 
three months. Data input and analysis were completed within two months of completion 
of study.  
Conclusion 
The purpose of this research study was to consider whether there are differences 
between medication management in older and younger adults living with HIV. The 
second purpose of this study was to identify factors that predict medication management 
so that nurses and other healthcare providers can consider these factors as they create 
strategies to promote medication management and increase adherence in their patients. In 
this chapter the methodology used has been identified, described and justified by the 
researcher. Findings from this study may help nurses and other healthcare providers 
create better strategies to increase older adults HIV medication management. 





The primary aim of this research was to examine if medication management is 
different for older adults living with Human Immunodeficiency Virus (HIV) compared to 
younger adults living with HIV. The secondary aim was to examine the relationship 
between age, personal factors (cognitive ability, depression, and self-efficacy) and 
medication management among participants. The two study aims were achieved through 
the following research questions. 
Question 1: Is there a difference in the medication management ability between older 
and younger adults living with HIV? 
Question 2: Are there differences in cognitive ability, depression, or self-efficacy 
between older and younger adults living with HIV? 
Question 3: What are the associations between personal factors (cognitive ability, 
depression, and self-efficacy) and medication management among older and younger 
adults living with HIV, respectively?  
Question 4: Which personal factors (cognitive ability, depression, and self-efficacy) are 
the best predictors of medication management among adults living with HIV, controlling 
for age as a covariate?  
Chapter four is organized into five sections: 1) recruitment and data management, 
2) sample characteristics, 3) quality of measures, 4) results to related questions, and  
5) discussion. 
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Recruitment and Data Management  
As explained in Chapter 3, participants were recruited from the Infectious Disease 
Clinic and the AIDS Clinical Trials Unit (ACTU) at Washington University School of 
Medicine. The researcher reviewed the clinic and ACTU schedules each day, using 
medical records to determine which persons with scheduled appointments would be 
eligible for the study. This initial identification consisted solely of age and HIV status. 
The researcher gave the research assistant employed by the ACTU a list of potentially 
eligible study participants. Potentially eligible participants were approached by the 
research assistant during their appointment and asked if they would be interested in 
participating in a research study designed to examine medication management in adults 
living with HIV. If interested, potential participants were instructed to come to the ACTU 
waiting room at the conclusion of their appointment and ask for the medication 
management researcher. The researcher brought the potential participant into a private 
room where eligibility was verified and the consent process took place. The majority of 
participants completed the research study at this time. Some persons interested in 
participating in the study scheduled appointments at a later date. 
Records were not kept on potential participants who declined to participate. In 
total 131 eligible participants completed the study. Of the eligible participants, one case 
in the younger group was excluded from analysis due to incomplete HIV-related medical 
data, resulting in 65 participants in the older group and 65 participants in the younger 
group for a total of 130 evaluable participants. Data was analyzed using SPSS version 
20.0 for Windows.  
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Table 6.  





Male  Female     
All G1 G2 All G1 G2     
 95(73%) 51(78%) 44(68%) 35(27%) 14(22%) 21(32%)     
Race Black  White  Other 
 All G1 G2 All G1 G2 All G1 G2 
82(63%) 34(52%) 48(74%) 47(36%) 31(48%) 16(25%) 1(1%) 0 1(2%) 
 Currently  In the Past  Never 
All G1 G2 All G1 G2 All G1 G2 
Alcohol use 80(62%) 32(49%) 48(74%) 38(29%) 26(40%) 12(18%) 12(19%) 7(11%) 5(8%) 
Tobacco use 65(50%) 24(37%) 41(63%)  34(26%) 26(40%) 08(12%)  23(18%) 7(11%) 16(25%) 
Drug use 38(29%) 13(20%) 25(39%)  41(32%) 22(34%) 19(29%)  51(39%) 30(46%) 21(32%) 
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Numerical  
Variables Range  Mean  Standard Deviation 
All G1 G2 All G1 G2 All G1 G2 
Age (Years) 20-76 50-76 20-49 46.91 56.17 37.65 11.67 6.01 8.02 
Education 
(Years) 
8-20 8-20 8-20  12.90 12.88 12.92  2.49 2.66 2.33 
HIV-Related Medical Data 
Years Since HIV 
Diagnosis 
1-30 3-30 1-28  13.74 15.80 11.68  7.39 7.62 6.60 
Years of HIV 
Meds 
1-28 1-28 1-27  9.28 10.50 08.05  6.50 6.55 6.27 
Current CD4 
Count 
5-1649 5-1417 8-1649  557.85 548.94 566.75  303.60 290.87 317.85 
Nadir CD4 Count 0-1289 0-600 0-1289  211.43 161.51 261.35  192.20 147.68 218.15 
Number of Meds 0-19 0-19 0-9  4.89 6.40 3.40  3.69 3.95 2.69 
Number of Other 
Diagnoses 
0-12 0-12 0-7  3.35 4.55 2.14  2.54 2.61 1.78 
Note: G1 – Group 1(Older adults); G2 = Group 2 (Younger adults); Number of Meds includes all documented medications other than HIV medications; Other 
Diagnoses includes all documented diagnoses other than HIV or AIDS 




 The characteristics of this sample are reflective of the current state of the HIV 
epidemic in this country (CDC, 2012). The older group consisted of more college 
educated White males than the younger group. While the majority of older participants 
were White males, the females enrolled in this group were predominantly Black.  
The younger group included more females and more Blacks than the older group. 
There were more than twice as many Black males as White males in this group, and the 
females in this group were overwhelmingly Black females. The younger group had 
higher rates of alcohol, tobacco and drug use than the older group.  
Table 6 summarizes demographic information and HIV-related medical data for 
all participants and each group. The 130 participants in this study each had a positive 
HIV test documented in their medical records. Among them, 95 (73%) were male and 35 
(27%) were female. Eighty-two participants (63%) were Black, 47 (36%) were White, 
and one self-identified as “other”. Eighty participants (61%) consumed alcohol, 38 (29%) 
reported past alcohol consumption and 12 (9%) reported never having consumed alcohol. 
Sixty-five participants (50%) smoked tobacco, 34 (26%) smoked in the past, but not 
currently, and 31 (24%) never smoked. Thirty-eight participants (29%) used drugs, 41 
(31%) had used drugs in the past, but not currently, and 51 (39%) never used drugs. On 
average, study participants were 46.9 years of age (SD = 11.67), ranging from 20 to 76 
years. Their mean years of education was 12.9 years (SD= 2.49), ranging from 8 to 20 
years. Overall 103 study participants (79%) had at least a high-school education, and 19 
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(15%) had college degrees. The average time since HIV diagnosis for all participants was 
13.74 years (SD = 7.39), ranging from one to 30 years. On average, study participants 
have taken HIV medications for 9.28 years (SD = 6.50), ranging from 1 to 30 years. The 
mean number of HIV medications taken each day was 2.4 (SD = 1.11), ranging from one 
to five. Overall three-quarters (n = 97; 75%) of the participants had undetectable viral 
loads, indicating the level of the HIV in the blood is below the level needed for detection, 
and demonstrating that it is well-controlled in the body. The remaining quarter (n = 33; 
25%) had detectable viral loads ranging from 20 to 206,397, indicating that HIV could be 
found in the blood, and the infection was not fully controlled by medication.  
In the older group (n = 65), there were 51 (78.5%) males and 14 (21.5%) females. 
Among them, 34 (52%) were Black and 31 (48%) were White. Almost half (n = 32; 49%) 
of the older adults consumed alcohol, 26 (40%) consumed alcohol in the past, but did not 
currently, and 7 (11%) reported never drinking alcohol. Twenty-four (37%) older adults 
used tobacco, 26 (40%) used tobacco in the past, but did not currently, and 15 (23%) 
never used tobacco. Thirteen (20%) older adults used drugs, 22 (34%) used drugs in the 
past, but did not currently, and 30 (46%) never used drugs.  
The average age of the older adults was 56.17 years (SD = 6.01), ranging from 50 
to 76 years. On average, they had 12.88 years of education (SD = 2.66), ranging from 
eight to 20. Three-quarters (n = 49; 75%) had at least a high school education and almost 
one in five (n = 12; 18%) had earned college degrees. Looking at gender, more than 
three-quarters (n = 42; 82%) of the older males had at least a high school education, and 
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less than a quarter (n = 11; 22%) had college degrees. Half (n = 7; 50%) of the older 
females had at least a high education, and just one (7%) had earned a college degree. 
The average time since HIV diagnosis was 15.80 years (SD = 7.62), ranging from 
3 to 30 years. The mean number of HIV medications they took each day was 2.35 (SD = 
1.14), ranging from 1 to 4 daily medications. The mean number of non-HIV medications 
taken each day was 6.40 (SD = 3.95), ranging from 0 to 19 non-HIV medications. Over 
two-thirds (n = 53; 82%) of the older adults had undetectable viral loads. The remaining 
12 (18%) had detectable viral loads ranging from 20 to 51,458. 
In the younger group (n = 65), there were 44 (68%) males and 21 (32%) females. 
Forty-eight (74%) participants were Black and16 (25%) were White. Forty-eight (74%) 
participants consumed alcohol, 12 (19%) consumed alcohol in the past, but did not 
currently, and 5 (8%) never consumed alcohol. Forty-one (63%) participants used 
tobacco, 8 (12%) used tobacco in the past, but did not currently, and 16 (25%) never used 
tobacco. Twenty-five (39%) participants used drugs, 19 (29%) used drugs in the past, but 
did not currently, and 21 (32%) never used drugs.  
The average age of the younger adults was 37.65 years (SD = 8.02), ranging from 
20 to 49 years. On average, they had 12.92 years of education (SD = 2.33), ranging from 
8 to 20 years of education. Over three-fourths (n = 54; 83%) had at least a high-school 
education, and seven (11%) had college degrees. Looking at gender, 37 (84%) younger 
males had at least a high school education, and seven (16%) had college degrees. Over 
three-quarters (n = 17; 81%) of the younger females had at least a high school education, 
none had a college degree. 
Frain, Judy, 2013, UMSL,   85 
 
The average time since HIV diagnosis was 11.68 years (SD = 6.60), ranging from 
1 to 28 years. The mean number of HIV medications they took each day was 2.45 (SD = 
1.09), ranging from 1 to 5 HIV medications. The mean number of non-HIV medications 
they took each day was 3.40 medications (SD = 2.69), ranging from 0 to 9. Overall 44 
(68%) younger adults had undetectable viral loads. The remaining 21 (32%) had 
detectable viral loads ranging from 22 to 206,397. 
Instrumentation 
 The measures used in this study were chosen because they had been used in other 
HIV studies, they were reliable and valid, and their brevity insured that participants 
would not be overly burdened in completing four survey instruments. Another important 
consideration was choosing instruments that could be transitioned into a clinical setting. 
Having brief, reliable instruments available would encourage their use during healthcare 
appointments. Healthcare providers have limited time to spend with their patients, and in 
order to incorporate survey instruments into a visit the instruments would have to be able 
to be completed quickly. Two of these instruments, the CES-D and the SE-CDS could be 
completed by the patient while in the waiting room, or while in the exam room waiting 
for the clinician. While the other two instruments, the MMT-R and the MoCA could be 
administered by a trained member of the healthcare team, and would not require a nurse 
or physician to administer. 
 Four measures were used in this study: the Montreal Cognitive Assessment 
(MoCA), the Center for Epidemiological Studies Depression Scale (CES-D), the 
Medication Management Task-Revised (MMT-R), and the Self-Efficacy for Chronic 
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Disease Scale (SE-CDS). The reliability of each instrument is documented in Table 7. 
Chronbach’s alpha was used to measure reliability of the CES-D, the MMT-R and the 
SE-CDS. Because of the way the MoCA is scored, with varying scales for each of the 
questions, Chronbach’s alpha was not a good fit in determining reliability. Therefore test-
retest was used to determine its reliability. Thirty of the study participants, 15 from each 
group, completed two separate MoCA tests. The tests were given no less than six months 
and no more than one year apart and were compared to determine test-retest reliability.  
The MoCA was used to measure cognitive ability. Scores on the MoCA range 
from 0 to 30, with a score of 26 or more considered normal and a score of less than 26 
considered mild cognitive impairment (Nasreddine et al., 2005). As shown in Table 6, the 
average MoCA scores demonstrate mild cognitive impairment for all participants (M = 
24.31; SD = 3.54), for the older group (M = 23.77; SD = 3.82), and for the younger group 
(M = 24.85; SD = 3.17). Individual total MoCA scores classified the study participants 
into normal cognitive ability (n = 47; 36%), and mild cognitive impairment (n = 83; 
64%). Among those with normal cognitive ability, 22 (47%) were older adults and 25 
(53%) were younger adults. Among those who exhibited mild cognitive impairment, 43 
(52%) were older adults, and 40 (48%) were younger adults.  
Regarding gender, more than three-quarters of females (n = 27; 77%) reported 
mild cognitive impairment, compared to about two-thirds of the males (n = 56; 62%). 
Similarly, in the older group; almost three-quarters of the females (n = 10; 71%) reported 
mild cognitive impairment, compared with about two-thirds of the males (n = 33; 65%). 
Following this trend, in the younger group over three-quarters of the females (n = 17; 
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81%) reported mild cognitive impairment compared to just over half the males (n = 23; 
52%).  
The CES-D was used to measure depression. Scores on the CES-D range from 0 
to 60, with a score of less than 16 considered no depression, scores of 16 to 22 considered 
mild depression, and scores of 23 or more considered major depression (Randloff, 1977). 
As shown in Table 7, the average overall CES-D scores were just below the level 
specified for clinical depression (M = 15.42; SD = 11.52), for the older group (M = 
15.84; SD = 12.80, and for the younger group (M = 15.00; SD = 10.16). Individual total 
CES-D scores found about half (n = 75; 58%) of the participants were not exhibiting 
symptoms of clinical depression, about a fifth (n = 28; 21%) of the participants were 
experiencing mild depressive symptoms, and another fifth (n = 28; 21%) were 
experiencing major depressive symptoms. Among participants who were not clinically 
depressed, about half (38; 51%) were older adults and half (n = 37; 49%) were younger 
adults. For those with mild depressive symptoms, 11 (39%) were older adults and 17 
(61%) were younger adults. Of those with major depressive symptoms, 16 (59%) were 
older adults and 11 (41%) were younger adults.  
Regarding gender, about a quarter of the males (n = 23; 24%) reported mild 
depressive symptoms, compared with 14% of the females (n = 5). However, the 
percentage of women reporting major depressive symptoms (n = 12; 34%) was more than 
double that of males (n = 15; 16%). A similar trend was found in the older group; where 
males (n = 9; 18%) and females (n = 2; 14%) had similar rates of mild depression, but a 
third of the females (n = 2; 33%) reported major depressive symptoms compared to a 
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fifth (n = 10; 20%) of the males. The trend continued in the younger group, where about 
one-third of males (n = 14; 32%) reported mild depressive symptoms compared to 14% 
of females (n = 3), but here again, the percentage of females reporting major depressive 
symptoms was nearly three times that of males (n = 6; 29% vs. n = 5; 11%).  
The MMT-R was used to measure medication management. Scores on the MMT-
R range from 0 to 16. A higher score indicates better medication management (Heaton et 
al., 2004). Total mean scores for all participants were 12.27 (SD = 3.31), for the older 
group the mean score was 12.17 (SD = 3.23) and for the younger group 12.52 (SD= 
3.30). Regarding gender, the mean score for males was 13.08 (SD = 2.83) with scores 
ranging from 4 to 16, and the mean score for females was 10.34 (SD = 3.53) with scores 
ranging from 3 to 16.  
Education was associated with scores on the MMT-R. Participants with a college 
degree had mean scores of 15.11 (SD = 1.15), with scores ranging from 12 to 16. Mean 
scores of high school graduates were 12.80 (SD = 3.29), ranging from 4 to 16. Mean 
scores of participants who did not finish high school were 10.22 (SD = 2.55), ranging 
from 3 to 16.  
The SE-CDS was used to measure self-efficacy. Scores on the SE-CDS range 
from 0 to 10, with higher scores indicating higher self-efficacy (Lorig et al., 2001). The 
total mean score was 7.76 (SD = 1.98), ranging from 1.33 to 10. The mean score for the 
older group was 12.17 (SD = 3.23) and for the younger group 12.52 (SD = 3.30). 
Regarding gender, the mean scores for males was 7.90 (SD = 1.99), ranging from 1.33 to 
10, and the mean score for females was 7.35 (SD = 1.91), ranging from 2.83 to 10.  
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Table 7. 
 Descriptive Statistics and Reliability of Study Instruments for All and by Groups 
  Range  Mean  SD Reliability 
Description  All  G1  G2 All  G1  G2 All  G1  G2  All  G1  G2 
MoCA 14-30 14-30 16-30 24.31 23.77 24.85 3.54 3.82 3.17 0.90  0.90  0.90 
CES-D 0-50 0-50 0-41 15.42 15.84 15.00 11.52 12.80 10.16  0.91  0.93  0.87 
MMT-R 3-16 3-16   4-16 12.27 12.17 12.52 3.31 3.23 3.30  0.80  0.78  0.81 
SE-CDS 1.33-10 2.5-10 1.33-10 7.75 7.68 7.83 1.98 2.06 1.90  0.92  0.93  0.91 
Note: G1 – Group 1 (Older group); G2 = Group 2 (Younger group); SD = standard deviation 
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Results Related to Research Questions 
Question 1 - Is there a difference in the medication management ability between 
older and younger adults living with HIV? 
 An independent t-test was used to answer research question 1.  The t-test was 
used to compare the mean scores on medication management between the older and 
younger groups. Data showed that the older group had a mean score of 12.17 (SD = 3.23) 
on medication management and the younger group had a mean score of 12.52 (SD = 
3.30). The older group scored lower in medication management ability than the younger 
group, however, the difference did not rise to the level of statistical significance and the 
effect size was minimal (Tables 7, 8). 
Question 2 - Are there differences in cognitive ability, depression, or self-efficacy 
between older and younger adults living with HIV? 
An independent t-test was used to answer research question 2. The t-tests were 
used to compare the mean scores on cognitive ability, depression and self-efficacy 
between the older and younger group (Table 7). On cognitive ability the mean score for 
older adults was 23.77 (SD = 3.82), the mean score for younger adults was 24.85 (SD = 
3.17). Scores greater than 26 indicate normal cognitive ability, and scores lower than 26 
indicate mild cognitive impairment. Both groups had a mean score below the 26 point 
cutoff, indicating mild cognitive impairment. This difference demonstrated a small effect 
size and was not statistically significant. 
On depression older adults had a mean score of 15.84 (SD = 12.80), younger 
adults had a mean score of 15.00 (SD = 10.16). Higher scores indicate a higher level of 
depression, a score higher than 16 indicates clinically meaningful depression. Overall 
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older adults exhibited more depression than younger adults. Although the difference did 
not rise to the level of statistical significance and the effect size was minimal. 
Scores on self-efficacy can range from 0 to 10. In this study, the mean score on 
self-efficacy for older adults was 7.68 (SD = 2.06), and the mean score for younger adults 
was 7.83 (SD = 1.90). Older adults exhibited lower self-efficacy than younger adults, but 
once again the difference did not reach the level of statistical significance and exhibited a 
minimal effect size.  
In summary, older adults did not perform as well as younger adults on any of the 
measures examined in this study. Older adults exhibited higher rates of depression, 
poorer medication management ability, less cognitive ability and lower self-efficacy, 
although none of the differences reached the level of statistical significance (Table 8). 
Table 8.  
Differences on Variables Between Groups 
 t Sig CI Effect Size 
Medication 
management 
-0.67 0.50 -1.52-0.75 0.05 
Cognitive 
ability 
-1.79 0.10 -2.33-0.17 0.15 
Depression 0.31 0.76 -3.39-4.65 0.04 
Self-efficacy -0.43 0.67 -0.88-0.54 0.04 
Note: Sig = significance; SD = standard deviation; CI = confidence interval 
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Question 3 - What are the associations between personal factors (cognitive ability, 
depression, and self-efficacy) and medication management among older and 
younger adults living with HIV, respectively? 
 Pearson correlation was used to answer research question 3Table 9 displays the 
intercorrelations among cognitive ability, depression and self-efficacy for older adults. 
Scores for cognitive ability and depression were correlated with medication management, 
both at p < .01; self-efficacy was correlated with depression at the p < .01 level. Self-
efficacy was not correlated with medication management. 
Table 9.  








- .641** -.383** .111 
Cognitive 
Ability 
 - -.212 -.006 
Depression   - -.586** 
Self-Efficacy    - 
**: Correlation is significant at the 0.01 level (2-tailed) 
Table 10 displays the intercorrelations between instruments for younger adults. 
Similar to older adults, cognition and depression were correlated with medication 
management, at the p < .01. In the younger adults, as in the older adults, self-efficacy was 
not correlated with medication management. In contrast to the results in older adults, self-
efficacy in younger adults was not correlated with depression. 
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Table 10.  








- .477** -.321** .108 
Cognitive 
Ability 
 - -.109 -.029 
Depression   - -.164 
Self-Efficacy    - 
**: Correlation is significant at the 0.01 level (2-tailed) 
Question 4 - Which personal factors (cognitive ability, depression, and self-efficacy) 
are the best predictors of medication management among adults living with HIV, 
controlling for age as a covariate? 
Multiple regressions were used to answer research question 4. Table 11 displays 
the summary of the model for older adults. As shown in Table 11, this model, with an 
adjusted R² of .45 (p < .001), suggests that 45% of the variance in medication 
management ability can be predicted by cognitive ability, depression and self-efficacy. 
The value of adjusted R² of .45 is considered to be a moderate to large effect size (Cohen 
& Cohen, 1983). Table 12 presents the analysis of variance (ANOVA) that indicates the 
overall significance of the model for the older adults. 
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Table 11.  
Model Summary Older Adults 
Predictor 
Variable 
R R² Adjusted 
R² 




.691* .478 .452 18.61 3,61 .000 
*Predictors: (Constant), Depression, Cognitive Ability, Self-Efficacy 
Table 12.  
Analysis of Variance for Model 1* 




F Sig. (p) 
Regression 318.78  3 106.261 18.61 .000** 
Residual 348.36 61   5.711   
Total 667.14 64    
*Dependent Variable: Medication Management  
**Predictors: (Constant), Cognitive Ability, Depression, Self-Efficacy 
While the total R square indicates the proportion of variance in the model 
accounted for in medication management, the squared semi-partial correlations (sr²) were 
employed to detect the variance uniquely accounted for by each individual variable. The 
unique variance does not include any of the variables shared variance. Results indicate 
that cognition accounted for 31% (sr²=.312) of the unique variance in medication 
management scores (β = .58, p < .001). Depression accounted for 6% (sr²=.055) of the 
unique variance (β = -.30, p < .05), and self-efficacy accounted for .3% (sr² = .003) of the 
variance (β = .05, p = .55). The results of semipartial correlations (sr²) for each predictor 
reveal that about 11% of the variance in the model was shared by the three predictors. 
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The same procedures with the same variables were then performed for younger 
adults. As shown in Table 13, this model, with an adjusted R² of .27, (p < .001), suggests 
that medication management can be predicted by cognitive ability and depression. Self-
efficacy was excluded from the model for younger adults. Thus, 27% of the variance in 
medication management can be predicted by cognitive ability and depression for younger 
adults. The value of adjusted R² of .27 is considered a small effect size (Cohen & Cohen, 
1983). While this result was significant, the predictive value of the three variables 
(cognition, depression and self-efficacy) for younger adults was considerably smaller 
than their predictive value for older adults. Table 14 presents the analysis of variance 
(ANOVA) that indicates the overall significance of the model for the younger adults. 
Table 13.  
Model Summary Younger Adults 
Predictor 
Variable 
R R² Adjusted 
R² 
F df Sig. (p) 
Regression 
Model 2 
.551* .304 .270 8.87 3,61 .000 
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Table 14. 
 Analysis of Variance for Younger Adults* 




F Sig. (p) 
Regression 211.49  3 70.50 8.87 .000** 
Residual 484.73 61  7.95   
Total 696.22 64    
*Dependent Variable: Medication Management  
**Predictors: (Constant), Cognitive Ability, Depression, Self-Efficacy 
Results of the squared semipartial correlations (sr²) in younger adults indicate that 
cognition accounted for 20% (sr²=.197) of the unique variance in medication 
management scores (β = .45, p < .001); depression accounted for 7% (sr²=.067) of the 
variance (β = -.26, p < .05); and self-efficacy accounted for .3% (sr² = .003) of the 
variance (β = .05, p = .63). From the results of semipartial correlations (sr²) for each 
variable, it appears that about 3% of the variance in the model was shared by the three 
variables. 
In order to generalize the findings to the general population, certain assumptions 
must be met. So, the assumptions of linear regression were tested.  
Tests for multicollinearity indicated that a low level of multicollinearity was 
present in both groups (Field, 2005). Older adults (Tolerance = .61, VIF = 1.63 for 
depression, Tolerance = .93, VIF = 1.07 for cognition, and Tolerance = .64, VIF = 1.59 
for self-efficacy). Younger adults (Tolerance = .97, VIF = 1.04 for depression, Tolerance 
= .99, VIF = 1.01 for cognition and Tolerance = .97, VIF = 1.03 for self-efficacy). 
Therefore, all variables were retained in the prediction models for each group. In older 
adults, both MoCA and CES-D were shown to be significant predictors of the outcome 
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variable, medication management. For MoCA: (B = .488, SE = .081) p < .001, CI = 
(.326, .650). For CESD: (B = -.076, SE = .30) p < .05, CI = (-.135, -.016). In younger 
adults, only MoCA was a significant predictor of the outcome variable, medication 
management. MoCA: (B = .613, SE = .110) p < .001, CI = (.394, .831) 
 Linearity was tested for each group between the predictors and the outcome 
variable, medication management. All relationships were linear, so all assumptions were 
retained in each group. Independence of errors was then tested for each group. A normal 
distribution was seen, so all the assumptions were retained. Finally, the errors were 
normally distributed, so all of the assumptions were retained. The data can be generalized 
to the population of persons living with HIV. 
Findings 
 Results indicate both the older and younger adults have high rates of mild 
cognitive impairment, high rates of depression, and high self-efficacy, and both groups 
had poor medication management ability. In both older and younger adults cognitive 
ability and depression were predictive of medication management, although each variable 
was a stronger predictor for older adults. Overall, cognitive ability was the best predictor 
of medication management for both older and younger adults, but again, a stronger 
predictor for older adults.  
Discussion of Results 
Differences in medication management ability. This study found no statistically 
significant difference in medication management between older and younger adults living 
with HIV. In fact, both older and younger adults performed poorly on the medication 
management test, answering only about 75% of the questions correctly. Many 
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participants in this study seemed quite confident in answering medication management 
questions. Less than a dozen of the 130 participants used the pen and paper provided to 
work out medication questions requiring calculations. Yet even simple calculations were 
problematic for many participants. Barely 60% (61.8%) of participants could correctly 
determine the number of days a refill would last if they were given 30 pills and the 
prescription on the label called for two pills per day. Only 71 (52%) participants were 
correctly able to set up one day’s worth of medications that consisted of four different 
medications, taken once, twice, or three times per day. 
In the only other study found that used the MMT-R to compare medication 
management ability between older and younger adults,  Thames et al. (2011) found older 
adults with HIV performed significantly worse than younger adults (p < .05). In 
comparing study results, the difference in scores between the younger groups was small, 
however the older group in Thames’ study scored much worse than the older group in the 
current study. The demographics of the two older groups were similar, except in the 
earlier study the mean age of the participants in the older group was 59.4, compared to 
56.1 in the current study. Another possibility for the differences between older groups is 
the ages within the group. The minimum age for the older group was 55 in the earlier 
study. Perhaps medication management is not affected until cognitive changes are more 
pronounced, and adults aged 50 to 55 may not be affected as much. Another possibility is 
that the age gap between the two groups was greater in the earlier study, so perhaps 
differences between the two groups were more pronounced. The previous study was also 
much smaller than the current study, with a total of 51 participants, so the results may not 
be generalizable to other populations.  
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A study by Waldrop-Valverde, Jones, Jayaweera, Gonzalez, Romero and Ownby 
(2009) used the original version of the MMT-R. Results were not presented by age, but 
were broken down by gender. Findings showed females scoring lower than males in 
medication management (p < .01). Results of this study support Waldrop-Valverde, et al. 
results. Females scored significantly worse than males (p < .001) in both the older and 
younger groups. These results of both of these studies emphasize the need to not only 
include women in HIV studies, but to analyze their data separately to capture differences 
associated with gender. 
This study defines medication management as: “the desire and ability to adhere to 
a medication regimen” (Madigan, Farris, Wiens, & Johnson, 2003). The majority of 
medication studies focus on adherence or compliance, and not specifically medication 
management, yet the goal of these studies remain the same; to determine how accurately 
medications are taken. Results of previous studies have overwhelming shown that older 
persons do a better job of taking medications correctly than younger persons (Barclay et 
al., 2007; Gorman et al., 2009; Hinkin et al., 2004; Maggiolo et al., 2002). These studies 
have found that older adults who are better able to manage their medications have 
generally relied on methods of measurement such as pill counts, patient recall or 
prescription refills. Methods that do not take into account the help some older adults 
receive in setting up their medications, or remembering to take their medications. Nor do 
those methods reflect the accuracy of taking medications at the correct time (Murray et 
al., 2004). Unlike other methods, the MMT-R focuses strictly on the ability to read 
medication labels and take medications according to instructions (Heaton et al., 2004). 
While no gold standard exists for measuring medication management, the MMT-R has 
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been shown to be an accurate measure of how adults take their medications (Albert et al., 
2003; Albert et al., 1999; Heaton et al., 2004).  
The medication management scores from this study suggest that regardless of age, 
medication management is a skill that needs to be fostered in adults living with HIV. 
Given that medication management scores for the older and younger groups averaged 
76% and 78% respectively, it is hard to imagine that the requisite 90-95% adherence rate 
for full viral suppression can be approached for either of these groups (Bartlett, 2002). 
 An additional concern is that older adults face the added challenge of having to 
take an increased number of medications due to numerous comorbidities. Studies have 
found that complex medication regimens are associated with poorer medication 
management (Hinkin et al., 2002; Maggiolo et al., 2002). This current study found a 
statistically significant difference in the mean number of medications other than HIV 
medications taken between older and younger adults; 6.4 versus 3.4 medications 
respectively (p < .001), suggesting that medication management may be even more 
important for older adults, since the number of their medications may continue to 
increase. Furthermore, since poor medication management is a major cause of 
hospitalizations in the older population (Swanlund, Scherck, Metcalfe, & Jesek-Hale, 
2008), improving medication management for older adults could decrease the number of 
hospital admissions with a subsequent decrease the cost of care. A study by Col, Fanale 
and Kronholm (1990) found that poor medication management accounted for 28% of all 
hospitalizations among older adults with 11% related to adherence issues. If healthcare 
providers can identify and work with older adults at risk for poor medication 
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management before adverse events or hospitalizations occur, then those adults may 
experience an improved quality of life and potentially decreased healthcare costs.  
Interestingly, in spite of poor medication management, mean CD4 counts were 
within normal range for the majority of participants (558 overall; 549 and 567 for older 
and younger adults respectively), and three quarters (75%) of participants had 
undetectable viral loads. The CD4 counts are a measure of the health of the immune 
system, and viral load is a measure of the amount of HIV virus in the blood. When CD4 
counts are above 500 they are considered normal for persons living with HIV. When CD4 
counts drop below 200 the immune system is no longer able to resist infections, and an 
AIDS diagnosis results. This may suggest that HIV medications, even when taken less 
than optimally, can effectively suppress the HIV virus in the body, and perhaps a less 
stringent medication adherence goal, rather than the existing goal of 90-95% could be 
effective in controlling the virus. 
Differences in cognitive ability, depression and self-efficacy. This study found 
no statistically significant differences in cognitive ability, depression or self-efficacy 
between older and younger adults with HIV. However older adults scored lower than 
younger adults on every variable measured in this study. While it was not unexpected that 
depression and self-efficacy would be similar between the two groups, it was thought that 
older adults would have lower cognitive scores than younger adults. Recent research has 
reported early cognitive changes in adults with HIV (Ances et al., 2010; Malaspinia et al., 
2011), and it was thought that decreased cognitive ability would be reflected by lower 
scores on the MoCA. This was not the case.  
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Cognitive ability. The scores on the MoCA in this study indicate the prevalence of 
mild cognitive impairment (scores < 26) in both older and younger adults (Nasreddine et 
al., 2005). There was a small effect size difference between the older and younger groups. 
Because recent research has demonstrated high rates of cognitive decline in adults with 
HIV as young as 45 years of age (Ances et al., 2010; Barclay et al., 2007; Malaspinia et 
al., 2011), it was thought there would be a significant difference in MoCA scores 
between the groups. However both groups in this sample had, on average, been diagnosed 
with HIV for over 10 years, and had been on HIV medications for an average of at least 
eight years. So it is possible that even the younger group in this sample experienced 
cognitive decline related to long-term HIV infection (Clifford, 2008; Price & Spudich, 
2008). Another possible explanation is that initial cognitive changes related to age may 
be too small to be detected by the MoCA, and would not show up on cognitive testing 
until further decline took place.  
Gender differences were seen in cognitive ability. When breaking down scores by 
age and gender, older females scored significantly worse than any of the other groups  
(p < .05). The scores for younger females were the next lowest. While some studies have 
explored gender differences in how HIV affects the body, and found slower disease 
progression for women (Jarrin et al., 2008; Nicastri et al., 2005) no studies were found 
that explored whether gender influences how HIV affects cognitive ability. These results 
suggest this may be an important area for future research. 
Depression. This study reinforces previous studies of depression in the HIV 
population in finding that depression rates were higher in adults with HIV than in adults 
living with other chronic diseases (Emlett, 2006b; Katon et al., 2010; Lichtman et al., 
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2008). High rates of depression were found in both the older and younger groups. In 
comparing older and younger adults living with HIV, there was no statistically significant 
difference in depression rates, although the rates were slightly higher in the older group. 
Previous studies have found older adults with HIV had higher rates of depression than 
younger adults (Kilbourne et al., 2002; Valente, 2003; Voss et al., 2007), yet other studies 
have reported higher rates in younger persons (Justice et al., 2004; Rabkin, 1996). This 
study offers no definitive answer as to whether older adults experience higher depression 
rates than younger adults, but supports previous studies calling attention to the high 
overall rates of depression for persons living with HIV. 
While the overall rates of depression were found to be high in both older and 
younger adults, the rate of major depressive symptoms was striking. A quarter (n = 16; 
25%) of older adults and almost one fifth (n = 11; 17%) of younger adults exhibited 
major depressive symptoms. Examining men exclusively, major depressive symptoms 
were nearly twice as prevalent among older men as younger men (20% vs 11% 
respectively).  
Rates of major depressive symptoms in women were even more disturbing; with 
rates more than double that of men in both the older and younger groups (29% vs 11% 
and 43% vs 20% respectively). Previous studies using the CES-D have also found higher 
rates of depression in women living with HIV (Cook et al., 2004; Richardson et al., 
2001), these studies associated depression with decreased medication adherence and 
increased AIDS-related mortality, making managing depression a critical component of 
caring for persons with HIV. 
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 This current study suggests that despite research emphasizing the benefits of 
treating depression, depression rates have not declined in the HIV population. Because 
women represent one of the fastest growing groups of persons living with HIV, and have 
the highest rates of depression this is a problem that cannot be ignored. These high rates 
of depression are a reflection of the work that still needs to be done to erase the stigma 
and shame that continues to be associated with an HIV diagnosis. Furthermore these 
results suggest a need for more vigilance in diagnosing and treating depression in all 
persons living with HIV, with a particular focus on women. 
Self-efficacy. Both older and younger adults registered high scores on the SE-
CDS. Surprisingly, these scores were significantly higher than scores reported in previous 
studies of persons living with chronic diseases. Lorig et al (2001) evaluated persons 
living with chronic diseases and reported a mean score of 5.17 (SD = 2.22), this compares 
to a mean score of 7.75 (SD = 1.98) in this sample. High scores indicate increased self-
efficacy for dealing with chronic disease, in this case HIV. Curiously, in this study self-
efficacy was not strongly correlated with medication management. This result was 
unexpected because most previous studies identified self-efficacy as important to health 
maintenance behaviors, including medication management (Brekke, Hjortdahl, & Kvien, 
2001; Grembowski et al., 1993; Sarkar, Fisher, & Schillinger, 2006). Bandura (1993) 
found people did not perform well if they lacked the necessary skills, or if they had the 
skills but lacked the self-efficacy needed to utilize them. In this study participants appear 
to have had the self-efficacy needed to perform well at medication management, but they 
may have lacked the necessary skills to do so.  
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Social Cognitive Theory postulates that perceived self-efficacy and outcome 
expectancies are important factors in influencing behavior (Bandura, 2004). However 
Bandura (1989) also states that along with self-efficacy, cognitive processing is necessary 
to affect behavior. Both older and younger participants in this study scored high on self-
efficacy, and yet in this study neither group performed particularly well on the test of 
medication management. One possible explanation can be gleaned from the Social 
Cognitive Theory that underpins this study (Figure 1). High self-efficacy was not enough 
to overcome the other personal factors (depression and low cognitive ability) that worked 
against mastery of medication management.  
The high self-efficacy shown by both groups in this study is encouraging. It 
demonstrates a strong belief in the ability to manage HIV, and suggests a willingness to 
improve medication management as part of overall disease management. However these 
results also suggest that high self-efficacy alone is not sufficient to master medication 
management. A person must possess the cognitive ability, in addition to the desire and 
motivation necessary to effectively manage their medications. Since it appears from these 
results that persons are motivated to excel at medication management, interventions 
targeted at improving functional and cognitive skills may prove effective.  
The SE-CDS was chosen for this study because it focuses on chronic disease, and 
its brevity makes it conducive for use in a clinical setting (Lorig et al., 2001). In 
retrospect, this scale may have been a poor fit for this patient population because the 
majority of the questions deal with disease symptoms. Though now considered by many 
to be a chronic disease, HIV differs from other chronic diseases in that persons infected 
can live for years without experiencing any noticeable, much less debilitating symptoms. 
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Future studies may benefit from the development of a brief self-efficacy scale tailored 
specifically for persons living with HIV, or possibly focused specifically on medication 
management for persons living with HIV. 
Associations between cognitive ability, depression and self-efficacy. In this 
study cognitive ability and depression were strongly correlated with medication 
management for both older and younger adults. This suggests that interventions designed 
to improve cognitive ability or decrease depression could improve medication 
management, thereby improving health-related quality of life.  
Self-efficacy was strongly correlated with depression for older adults, but had no 
correlation for younger adults. The strong correlation between depression and self-
efficacy found in older adults reinforces findings from previous studies (Bandura, 1993; 
Emlet, 2007; Grov, Golub, Parsons, Brennan, & Karpiak, 2010). Surprisingly, there was 
no correlation between depression and self-efficacy in the younger adult group. Overall 
this group was in relatively good health and had few comorbidities, so this scale may not 
have effectively measured self-efficacy in relation to HIV disease. The scale measured 
chronic disease self-efficacy, and it may be that this group’s HIV was largely 
asymptomatic, so self-efficacy was high in relation to their disease management.  
Predictors of medication management ability. In both older and younger adults 
the three independent variables; cognitive ability, depression and self-efficacy were 
predictors of medication management. However the predictive value of these variables 
was much stronger for older adults. Together the three independent variables accounted 
for 45% of the variance in medication management scores for older adults, and 27% of 
the variance in younger adults. Cognitive ability was the strongest predictor of 
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medication management in both older and younger groups. But the predictive value was 
much stronger in older adults, where cognitive ability alone accounted for 31% of the 
variability in medication management. In contrast, cognitive ability accounted for 20% of 
the variance in younger adults, and while 20% variance is still a very strong correlation, it 
is not as robust as in older adults.  
This study supports the findings of previous studies by Barclay et al. (2007) and 
Ettenhofer et al. (2009) that found cognitive ability was the best predictor of medication 
management in older adults. However while Barclay et al. found cognitive ability the 
only predictor of medication management, this current study found depression and self-
efficacy were also predictive of medication management.  
Depression was strongly correlated with medication management, and accounted 
for about 6 to 7% of the variance in both older and younger groups. This result tracks 
with previous studies that found a strong association between depression and medication 
management (Holstad et al., 2010; Willard, 2006). Unexpectedly, self-efficacy accounted 
for just .3% of the variance in each group, and was not statistically significant. Past 
studies have shown self-efficacy has a strong correlation with medication management 
(Bandura, 1989; Horberg et al., 2008).  The results of the current study may be reflective 
of a strong belief in the ability to manage medications, despite the lack of cognitive 
ability necessary to accomplish this task. Persons in this study appeared confident in their 
answers when completing the medication management component of the study, even 
when those answers were wrong. 
Another possibility, as mentioned previously, the self-efficacy scale used in this 
study may have been a poor fit in judging medication management, since it was 
Frain, Judy, UMSL, 2013,   108 
 
developed for chronic illness and not HIV specifically. This may have caused inflated 
self-efficacy scores due to the asymptomatic nature of HIV. 
Social cognitive theory. Results from this study reinforced the personal and 
environmental factors of Social Cognitive Theory and its influence on behavior. These 
results add to current thinking about Social Cognitive Theory by emphasizing the role of 
cognition in behavior. Study findings suggest that the cognitive process of Social 
Cognitive Theory should be emphasized over personal and environmental factors. While 
discussion on this theory focuses on the importance of self-efficacy, findings from this 
current study suggest that  high self-efficacy by itself was not enough to successfully 
overcome high rates of depression and mild cognitive impairment in order to manage 
medications effectively. Despite the belief of many participants that they were able to 
answer medication management questions correctly, the average score on the medication 
management test was approximately 75%. Since medications must be taken correctly 90 
to 95% of the time, a score of 75% is indicative of the need to improve medication 
management. Healthcare providers, more specifically nurses, have the opportunity to 
impact personal and environmental factors that influence medication management. 
Recognizing that early assessment of changes in cognitive ability and depression can 
improve medication management puts nurses on the front line in the battle to improve 
medication management and adherence. Healthcare providers can also influence 
environmental factors that affect medication management by involving family members 
or friends to assist with medications when cognitive ability or depression inhibits the 
patient’s ability to manage medications on their own.  
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This study advances Social Cognitive Theory by validating the importance of the 
cognitive process in behavior.  While personal and environmental factors are important in 
affecting behavior, they cannot operate without the cognitive process. The results of this 
study suggest that the cognitive process is of primary importance in affecting behavior, 
and personal and environmental factors play a secondary role. A person must first be able 
to cognitively process the necessary steps to affect behavior. Nursing science would do 
best to concentrate on interventions that improve the cognitive process before developing 
interventions designed to affect personal or environmental factors. 
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Chapter 5 
Summary, Conclusions, and Implications 
Summary of the Purpose 
The primary aim of this research was to examine if medication management is 
different for older adults living with Human Immunodeficiency Virus (HIV) compared to 
younger adults living with HIV. The secondary aim was to examine the relationship 
between age, personal factors (cognitive ability, depression, and self-efficacy) and 
medication management among participants. The two study aims were achieved through 
the following research questions: 
Question 1: Is there a difference in the medication management ability between older 
and younger adults living with HIV? 
Question 2: Are there differences in cognitive ability, depression, or self-efficacy 
between older and younger adults living with HIV? 
Question 3: What are the associations between personal factors (cognitive ability, 
depression, and self-efficacy) and medication management among older and younger 
adults living with HIV, respectively?  
Question 4: Which personal factors (cognitive ability, depression, and self-efficacy) are 
the best predictors of medication management among adults living with HIV, controlling 
for age as a covariate?  
This chapter summarizes the findings from the present study and discusses the 
implications and limitations. Additionally, recommendations for future research are 
presented as well. 
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Implications 
This study supports a relationship between personal factors; (cognitive ability, 
depression and self-efficacy) and medication management in adults living with HIV. 
Early assessment of cognitive ability and identification and treatment of depression could 
increase medication management and possibly decrease morbidity and mortality. 
Utilizing the research instruments at assessment tools at each healthcare appointment 
could provide a quick, effective way for nurses and other healthcare providers to assess 
subtle changes in personal factors (cognitive ability, depression and self-efficacy). 
Recording results at each healthcare visit and comparing scores over time could provide 
measurable evidence of changes that could affect medication management for patients. 
Thus, adults living with HIV would benefit from healthcare providers who incorporate 
these assessments into each patient visit.  
 Changes in healthcare, along with the improved overall health of adults living 
with HIV have led to a reduction in the frequency and the duration of healthcare visits for 
patients living with HIV. As a result, nurses and other healthcare providers have less time 
for assessing changes in cognitive ability and depression that could adversely affect 
medication management. Failure to recognize these changes could result in patients 
taking their medications incorrectly over extended periods of time. Errant or failed 
medication management may lead to the development of drug resistance and virologic 
failure, resulting in the need for more complex dosing regimens. A more complex dosing 
regimen makes medication management even more difficult for patients. This study 
suggests that early identification and intervention may stop or at least slow down 
undesirable, possible fatal effects of poor medication management. Findings from this 
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study also question the need for exacting regimens requiring 90-95% adherence.  New 
medications may be more forgiving than older ART, and perhaps a lower adherence rate 
will still keep the HIV virus suppressed. 
Suggestions for Future Research 
The results of this study suggest many areas ripe for research (Figure 2). These 
areas include: age-related factors, cognitive-related factors, depression-related factors, 
gender-related factors, and understanding the complexity of medication and medication 
management. Development of an HIV-specific self-efficacy scale, or medication 
management self-efficacy scale should be considered as well. 
It would be interesting to examine medication management in chronic diseases 
other than HIV to see whether it is similar to or different than in HIV, and whether the 
predictors of medication management are the same in other chronic diseases. If cognitive 
ability is the strongest predictor of medication management in other chronic diseases, it 
could be beneficial to know if other chronic diseases affect cognitive ability.  
Future studies could examine age-related cognitive changes that may affect 
medication management by using more narrowly defined age classifications. As medical 
advances lead to increases in life expectancy for persons living with HIV, it may make 
sense for HIV researchers to adopt the age classifications used in social work and 
gerontological medicine (Hutchison, 2007). In these fields, old age is broken down into 
young old (65-74), middle old (75-84) and old old (85 and older). Incorporating these 
classifications into HIV studies may provide a more specific measure of age-related 
cognitive changes, and could facilitate comparing adults living with HIV to adults living 
with other chronic diseases. 
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Results from this study demonstrate that medication management is a problem for 
both older and younger adults living with HIV. A secondary analysis of the data from this 
study could show that specific cognitive ability, rather than age related cognitive decline 
is an indicator of medication management. Using this data to identify those at risk for 
poor medication management could lead to earlier interventions. Future research could 
then explore the effectiveness of specific cognitive interventions designed to improve 
medication management for persons determined to be at risk for poor medication 
management. Successful early interventions could improve medication management 
thereby decreasing drug resistance caused by poor adherence.  
A recent pilot study by Vance, Fazeli, Ross, Wadley and Ball (2012) examined 
cognitive remediation therapy on a small group of middle-aged and older adults living 
with HIV and found that those in the experimental group improved on some cognitive 
measures, suggesting this type of training might improve cognitive and everyday 
functioning. This type of training is common in gerontology practice, but has not been 
used in the aging HIV population. Given the promising results from this pilot study, 
further research with this type of cognitive training in relation to medication management 
appears warranted.  
Another area for future research would be exploring which cognitive domains 
tested on the MoCA (attention, concentration, executive function, memory, language, 
visioconstructional skills, conceptual thinking, calculations, or orientation) have the 
greatest impact on medication management. If a secondary analysis found that specific 
cognitive domains have greater impact on medication management, mental exercises 
could then be developed for use by patients to help improve cognitive function in that 
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specific area, with the outcome of improving medication management. It may also be 
found that while cognitive decline begins earlier in persons living with HIV, those 
declines are not in areas that greatly affect medication management, but may affect other 
aspects of living with HIV. 
Though this study did not explore the impact of health literacy on medication 
management, results suggest that many participants experienced difficulties with 
interpreting prescription labels on medication bottles. Health literacy may have played a 
role in that difficulty. Future studies on medication management could include a health 
literacy component to determine if health literacy impacts medication management. It 
may be that changing the way medications are labeled could improve medication 
management. It would be worthwhile to test different medication labels to determine if 
written instructions affect medication management. 
Qualitative studies exploring why persons do not take their medications as 
prescribed have been done in the past. Now that medications are easier to take and side-
effects for many have decreased, it may be time to re-examine this issue in order to 
understand medication management from the patient’s perspective. 
Another question for future studies is why depression appears to be so 
undertreated in this population. Many persons displaying depression were receiving no 
antidepressant medications. Many who were receiving antidepressant medications still 
exhibited depressive symptoms. Many persons with depressive symptoms had no 
diagnosis of depression in their medical records. Qualitative studies may be the best 
method for considering reasons depression is under-diagnosed and under-treated in this 
population. 
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Developing an HIV-specific self-efficacy scale could improve this measure in 
future studies examining self-efficacy in persons living with HIV. While HIV is 
considered a chronic disease, it is different enough from other chronic diseases that a 
scale tailored to the specific problems of living with HIV could be a useful tool for 
measuring self-efficacy in this population. 
This study uncovered substantial differences between men and women living with 
HIV. Further examination of these differences should be a priority. Women are one of the 
fastest growing groups of persons living with HIV, and historically women have been 
underrepresented in HIV research, examining the specific needs of women should be an 
emphasis area for research.  
Although this research was not designed to examine differences between genders, 
in every measure analyzed women performed worse than men, and in some areas 
significantly so. Women experienced major depressive symptoms at more than twice the 
rate of men, and older women were nearly three times more likely to experience major 
depressive symptoms than were older men. The reasons for this might best be examined 
through qualitative studies exploring women’s perceptions of living with HIV.  
More than three-quarters of the women in this study exhibited cognitive 
impairment. Since cognitive ability was the best predictor of medication management, 
these results suggest that medication management will be challenging for women living 
with HIV. Scores on the medication management component of this study support these 
findings. Both older and younger women scored significantly lower than men in 
medication management (p < .001). Qualitative studies focused on women may be the 
best way to explore women’s perspective about their medications, how much importance 
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they place on taking their medications, and why they do or do not take them as 
prescribed.  
Women scored lower on the self-efficacy instrument than men. Even though self-
efficacy scores were generally high, reasons for this discrepancy could be explored. 
Qualitative studies where women would have the opportunity to give voice to their ability 
to effectively manage their HIV may be beneficial. Women should be well-represented in 
any research designed to develop an effective self-efficacy tool for persons living with 
HIV 
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There are limitations in the present study. Although the infectious disease clinic 
and clinical trials unit used for recruitment for this study draw from a sizable area in the 
Midwest, it is a single geographical site, which makes it more difficult to generalize the 
findings. However the demographics of the sample in this study are similar to national 
demographics of adults living with HIV.  
Because of the wide variety of instruments used in HIV studies it is difficult to 
compare results of this study to past studies. The instruments used in this study to 
measure depression (CES-D), cognitive ability (MoCA) and self-efficacy (SE-CDS) are 
not HIV-specific instruments, and other studies have used different instruments to 
measure these variables. While comparisons to other studies can still be made, they may 
not be as accurate due to the variation in instrumentation.  
Another limitation to the study was the higher percentage of women in the 
younger group may have skewed results in that group. Overall women did not perform as 
well as men on any of the study instruments. The greater number of women in the 
younger group may have resulted in lower overall scores in that group than would have 
been the case if men and women were equally represented in each group. It is worth 
noting that these percentages are reflective of the national HIV population.  
Finally, the self-efficacy scale used in this study may not have been a good fit for 
this patient population, and may have overestimated the confidence study participants had 
in managing their medications and their disease. As mentioned previously an HIV-
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specific self-efficacy scale may be important in accurately measuring self-efficacy in this 
population. 
Summary and Conclusion 
 This study considered whether there is a difference in medication management 
ability between older and younger adults living with HIV. It examined the influence of 
age in the relationships between cognition, depression, and self-efficacy and medication 
management. Past research suggested that medication management would be influenced 
by these variables. The literature suggested that these variables would be more 
pronounced in older adults living with HIV, and therefore affect medication management 
to a greater extent in that group. The results suggest that older adults have more difficulty 
managing their medications than younger adults, but the difference did not rise to a 
statistically significant level. In both groups cognitive ability was the best predictor of 
medication management, followed by depression and then self-efficacy. Cognitive ability 
was a stronger predictor in older adults than in younger adults, while depression and self-
efficacy were similar between the two groups.  
 These results emphasize the need to improve medication management for all 
persons living with HIV, with a particular focus on older adults and women. Older adults, 
often have numerous comorbidities, and face the challenge of managing their medications 
even with the complexity of their regimen. Women, one of the fastest growing groups of 
persons living with HIV, score lowest on medication management, depression and self-
efficacy,and may need special attention to help them successfully manage this disease. 
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SCORING: zero for answers in the first column, 1 for answers in the second column, 2 
for answers in the third column, 3 for answers in the fourth column. The scoring of 
positive items is reversed. Possible range of scores is zero to 60, with the higher scores 
indicating the presence of more symptomatology.  
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Appendix B 
Medication Management Task-Revised 
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Appendix C 
Montreal Cognitive Assessment 
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Montreal Cognitive Assessment 
(MoCA) 
Administration and Scoring Instructions 
The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening 
instrument for mild 
cognitive dysfunction. It assesses different cognitive domains: attention and 
concentration, executive 
functions, memory, language, visuoconstructional skills, conceptual thinking, 
calculations, and 
orientation. Time to administer the MoCA is approximately 10 minutes. The total possible 
score is 30 
points; a score of 26 or above is considered normal. 
1. Alternating Trail Making: 
Administration: The examiner instructs the subject: "Please draw a line, going from a 
number 
to a letter in ascending order. Begin here [point to (1)] and draw a line from 1 then to A 
then to 2 and so on. End here [point to (E)]." 
Scoring: Allocate one point if the subject successfully draws the following pattern: 
1 −A- 2- B- 3- C- 4- D- 5- E, without drawing any lines that cross. Any error that is not 
immediately self-corrected earns a score of 0. 
2. Visuoconstructional Skills (Cube): 
Administration: The examiner gives the following instructions, pointing to the cube: 
“Copy this 
drawing as accurately as you can, in the space below”. 
Scoring: One point is allocated for a correctly executed drawing. 
• Drawing must be three-dimensional 
• All lines are drawn 
• No line is added 
• Lines are relatively parallel and their length is similar (rectangular prisms are accepted) 
A point is not assigned if any of the above-criteria are not met. 
3. Visuoconstructional Skills (Clock): 
Administration: Indicate the right third of the space and give the following instructions: 
“Draw 
a clock. Put in all the numbers and set the time to 10 past 11”. 
Scoring: One point is allocated for each of the following three criteria: 
• Contour (1 pt.): the clock face must be a circle with only minor distortion acceptable 
(e.g., 
slight imperfection on closing the circle); 
• Numbers (1 pt.): all clock numbers must be present with no additional numbers; 
numbers 
must be in the correct order and placed in the approximate quadrants on the clock face; 
Roman 
numerals are acceptable; numbers can be placed outside the circle contour; 
• Hands (1 pt.): there must be two hands jointly indicating the correct time; the hour hand 
must 
be clearly shorter than the minute hand; hands must be centred within the clock face 
with their 
junction close to the clock centre. 
A point is not assigned for a given element if any of the above-criteria are not met. 
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Administration: Beginning on the left, point to each figure and say: “Tell me the name of 
this 
animal”. 
Scoring: One point each is given for the following responses: (1) lion (2) rhinoceros or 
rhino 
(3) camel or dromedary. 
5. Memory: 
Administration: The examiner reads a list of 5 words at a rate of one per second, giving 
the 
following instructions: “This is a memory test. I am going to read a list of words that 
you 
will have to remember now and later on. Listen carefully. When I am through, tell 
me 
as many words as you can remember. It doesn’t matter in what order you say 
them”. 
Mark a check in the allocated space for each word the subject produces on this first trial. 
When 
the subject indicates that (s)he has finished (has recalled all words), or can recall no 
more 
words, read the list a second time with the following instructions: “I am going to read the 
same 
list for a second time. Try to remember and tell me as many words as you can, including 
words 
you said the first time.” Put a check in the allocated space for each word the subject 
recalls 
after the second trial. 
At the end of the second trial, inform the subject that (s)he will be asked to recall these 
words 
again by saying, “I will ask you to recall those words again at the end of the test.” 
Scoring: No points are given for Trials One and Two. 
6. Attention: 
Forward Digit Span: Administration: Give the following instruction: “I am going to say 
some 
numbers and when I am through, repeat them to me exactly as I said them”. Read the 
five 
number sequence at a rate of one digit per second. 
Backward Digit Span: Administration: Give the following instruction: “Now I am going to 
say 
some more numbers, but when I am through you must repeat them to me in the 
backwards 
order.” Read the three number sequence at a rate of one digit per second. 
Scoring: Allocate one point for each sequence correctly repeated, (N.B.: the correct 
response for 
the backwards trial is 2-4-7). 
Vigilance: Administration: The examiner reads the list of letters at a rate of one per 
second, 
after giving the following instruction: “I am going to read a sequence of letters. Every 
time I 
Frain, Judy, UMSL, 2013,   180 
 
say the letter A, tap your hand once. If I say a different letter, do not tap your hand”. 
Scoring: Give one point if there is zero to one errors (an error is a tap on a wrong letter 
or a 
failure to tap on letter A). 
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Serial 7s: Administration: The examiner gives the following instruction: “Now, I will ask 
you to 
count by subtracting seven from 100, and then, keep subtracting seven from your 
answer until I 
tell you to stop.” Give this instruction twice if necessary. 
Scoring: This item is scored out of 3 points. Give no (0) points for no correct 
subtractions, 1 
point for one correction subtraction, 2 points for two-to-three correct subtractions, and 3 
points 
if the participant successfully makes four or five correct subtractions. Count each correct 
subtraction of 7 beginning at 100. Each subtraction is evaluated independently; that is, if 
the 
participant responds with an incorrect number but continues to correctly subtract 7 from 
it, give 
a point for each correct subtraction. For example, a participant may respond “92 – 85 – 
78 – 71 
– 64” where the “92” is incorrect, but all subsequent numbers are subtracted correctly. 
This is 
one error and the item would be given a score of 3. 
7. Sentence repetition: 
Administration: The examiner gives the following instructions: “I am going to read you a 
sentence. Repeat it after me, exactly as I say it [pause]: I only know that John is the 
one to 
help today.” Following the response, say: “Now I am going to read you another 
sentence. 
Repeat it after me, exactly as I say it [pause]: The cat always hid under the couch 
when dogs 
were in the room.” 
Scoring: Allocate 1 point for each sentence correctly repeated. Repetition must be exact. 
Be 
alert for errors that are omissions (e.g., omitting "only", "always") and 
substitutions/additions 
(e.g., "John is the one who helped today;" substituting "hides" for "hid", altering plurals, 
etc.). 
8. Verbal fluency: 
Administration: The examiner gives the following instruction: “Tell me as many words as 
you 
can think of that begin with a certain letter of the alphabet that I will tell you in a moment. 
You 
can say any kind of word you want, except for proper nouns (like Bob or Boston), 
numbers, or 
words that begin with the same sound but have a different suffix, for example, love, 
lover, 
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loving. I will tell you to stop after one minute. Are you ready? [Pause] Now, tell me as 
many 
words as you can think of that begin with the letter F. [time for 60 sec]. Stop.” 
Scoring: Allocate one point if the subject generates 11 words or more in 60 sec. Record 
the 
subject’s response in the bottom or side margins. 
9. Abstraction: 
Administration: The examiner asks the subject to explain what each pair of words has in 
common, starting with the example: “Tell me how an orange and a banana are alike”. If 
the 
subject answers in a concrete manner, then say only one additional time: “Tell me 
another way 
in which those items are alike”. If the subject does not give the appropriate response 
(fruit), 
say, “Yes, and they are also both fruit.” Do not give any additional instructions or 
clarification. 
After the practice trial, say: “Now, tell me how a train and a bicycle are alike”. Following 
the 
response, administer the second trial, saying: “Now tell me how a ruler and a watch are 
alike”. 
Do not give any additional instructions or prompts. 
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Scoring: Only the last two item pairs are scored. Give 1 point to each item pair correctly 
answered. The following responses are acceptable: 
Train-bicycle = means of transportation, means of travelling, you take trips in both; 
Ruler-watch = measuring instruments, used to measure. 
The following responses are not acceptable: Train-bicycle = they have wheels; 
Rulerwatch 
= they have numbers. 
10. Delayed recall: 
Administration: The examiner gives the following instruction: “I read some words to you 
earlier, which I asked you to remember. Tell me as many of those words as you can 
remember.” Make a check mark ( √ ) for each of the words correctly recalled 
spontaneously 
without any cues, in the allocated space. 
Scoring: Allocate 1 point for each word recalled freely without any cues. 
Optional: 
Following the delayed free recall trial, prompt the subject with the semantic category cue 
provided below for any word not recalled. Make a check mark ( √ ) in the allocated 
space if the 
subject remembered the word with the help of a category or multiple-choice cue. Prompt 
all 
non-recalled words in this manner. If the subject does not recall the word after the 
category cue, 
give him/her a multiple choice trial, using the following example instruction, “Which of the 
following words do you think it was, NOSE, FACE, or HAND?” 
Use the following category and/or multiple-choice cues for each word, when appropriate: 
FACE: category cue: part of the body multiple choice: nose, face, hand 
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VELVET: category cue: type of fabric multiple choice: denim, cotton, velvet 
CHURCH: category cue: type of building multiple choice: church, school, hospital 
DAISY: category cue: type of flower multiple choice: rose, daisy, tulip 
RED: category cue: a colour multiple choice: red, blue, green 
Scoring: No points are allocated for words recalled with a cue. A cue is used for 
clinical 
information purposes only and can give the test interpreter additional information about 
the 
type of memory disorder. For memory deficits due to retrieval failures, performance can 
be 
improved with a cue. For memory deficits due to encoding failures, performance does 
not 
improve with a cue. 
11. Orientation: 
Administration: The examiner gives the following instructions: “Tell me the date today”. If 
the 
subject does not give a complete answer, then prompt accordingly by saying: “Tell me 
the 
[year, month, exact date, and day of the week].” Then say: “Now, tell me the name of 
this 
place, and which city it is in.” 
Scoring: Give one point for each item correctly answered. The subject must tell the exact 
date 
and the exact place (name of hospital, clinic, office). No points are allocated if subject 
makes 
an error of one day for the day and date. 
TOTAL SCORE: Sum all subscores listed on the right-hand side. Add one point for an 
individual who has 12 years or fewer of formal education, for a possible maximum of 30 
points. 
A final total score of 26 and above is considered normal.  
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Appendix D 
Self Efficacy Scale 
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 Self-Efficacy for Managing Chronic Disease 6-Item Scale  
We would like to know how confident you are in doing certain activities. For each of the 
following questions, please choose the number that corresponds to your confidence that 
you can do the tasks regularly at the present time. 
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 Self-Efficacy for Managing Chronic Disease 6-Item Scale 
We would like to know how confident you are in doing certain activities. For each of the following 
questions, please choose the number that corresponds to your confidence that you can do the tasks 
regularly at the present time. 
1.   How confident are you that you can keep the fatigue caused by 
your disease from interfering with the things you want to do? 
Not at all 
confident 
1 2 3 4 5 6 7 8 9 10 Totally 
confident 
  
Items (using the same format as above): 
1. How confident are you that you can keep the fatigue caused by your disease from 
interfering with the things you want to do?  
2. How confident are you that you can keep the physical discomfort or pain of your disease 
from interfering with the things you want to do?  
3. How confident are you that you can keep the emotional distress caused by your disease 
from interfering with the things you want to do?  
4. How confident are you that you can keep any other symptoms or health problems you have 
from interfering with the things you want to do?  
5. How confident are you that you can do the different tasks and activities needed to manage 
your health condition so as to reduce you need to see a doctor?  
6. How confident are you that you can do things other than just taking medication to reduce 
how much you illness affects your everyday life?  
Scoring 
The score for each item is the number circled. If two consecutive numbers are circled, code the lower 
number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the 
scale is the mean of the six items. If more than two items are missing, do not score the scale. Higher 
number indicates higher self-efficacy. 
Characteristics 
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6  1-10  5.17  2.22  .91  NA  
 
Source of Psychometric Data 
Stanford/Garfield Kaiser Chronic Disease Dissemination Study. Psychometrics reported in: Lorig KR, Sobel, 
DS, Ritter PL, Laurent, D, Hobbs, M. Effect of a self-management program for patients with chronic disease. 
Effective Clinical Practice, 4, 2001,pp. 256-262. 
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INFORMED CONSENT DOCUMENT 
 
Project Title: A Comparison of Medication Management Between Older and 
Younger Adults Living With HIV 
Principal Investigator: Judy Frain 
Research Team Contact: Judy Frain  314.302.0875 
This consent form describes the research study and helps you decide if you want to 
participate. It provides important information about what you will be asked to do during 
the study, about the risks and benefits of the study, and about your rights as a research 
participant. By signing this form you are agreeing to participate in this study. 
• If you have any questions about anything in this form, you should ask the 
research team for more information.  
• You may also wish to talk to your family or friends about your participation in 
this study. 
• Do not agree to participate in this study unless the research team has answered 
your questions and you decide that you want to be part of this study.  
 
WHAT IS THE PURPOSE OF THIS STUDY? 
This is a research study. We invite you to participate in this research study because you 
have HIV and are taking antiretroviral medications. 
 The purpose of this research study is to determine if there are significant differences in 
medication management between older and younger adults living with HIV. The research 
will look to see if there are differences in cognitive ability, depression and self-efficacy 
between older and younger adults living with HIV, and if so what effect these have on 
medication management in these two groups. As more people with HIV are living to an 
older age determining differences between older and younger people with regard to how 
they take their medications will help us provide better care for these patients 
WHAT  WILL HAPPEN DURING THIS STUDY? 
• If you are eligible for the study you will complete the following evaluations: 
• A demographic form, which collects information about your age, ethnicity, education, 
HIV and other diseases you may have, the medications you take, and your alcohol, 
tobacco and drug history. This takes about 10 minutes. 
• The Montreal Cognitive Assessment, which asks questions about how you think. This 
takes about 10 minutes. 
• The Medication Management Task-Revised, which asks questions about taking 
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medications. This takes about 10 minutes. 
• The chronic disease self-efficacy scale, which asks questions about your confidence 
in performing certain activities. This takes about 5 minutes. 
• The Center for Epidemiologic Studies Depression Scale, which asks about your mood 
over the past week. This takes about 5 minutes. 
 
All questionnaires will be completed in a private exam room in the ACTU. 
You may skip any questions that may make you feel uncomfortable. 
HOW MANY PEOPLE WILL PARTICIPATE? 
Approximately 130 people will take part in this study conducted by investigators at 
Washington University.  
HOW LONG WILL I BE IN THIS STUDY? 
If you agree to take part in this study, your involvement will last for about one hour. 
WHAT ARE THE RISKS OF THIS STUDY? 
You may experience one or more of the risks indicated below from being in this study. In 
addition to these, there may be other unknown risks, or risks that we did not anticipate, 
associated with being in this study. 
• Risk of Social Harm 
Although the study site will make every effort to protect participant privacy and 
confidentiality, it is possible that participants’ involvement in the study could become 
known to others, and that social harms may result (i.e., because participants could 
become labeled as HIV-infected or at “high risk” for HIV infection). For example, 
participants could be treated unfairly or discriminated against, or could have problems 
being accepted by their families and/or communities 
WHAT ARE THE BENEFITS OF THIS STUDY? 
You will not benefit from being in this study. 
However, we hope that, in the future, other people might benefit from this study because 
it will increase our understanding of the effects of aging on HIV. 
 
WHAT OTHER OPTIONS ARE THERE?   
Taking part in this research study is voluntary. You may choose not to take part in this 
research study. 
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WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
You will not have any [costs/additional costs] for being in this research study.   
WILL I BE PAID FOR PARTICIPATING? 
You will be paid for being in this research study. You will receive $10 cash in 
remuneration for your participation in this study. This will be given to you at the 
completion of the study visit. You may choose to participate without being paid. 
WHO IS FUNDING THIS STUDY? 
This study is being funded by a joint grant from Sigma Theta Tau (The Nursing 
Honor Society) and the Association of Nurses in AIDS Care. 
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
We will keep your participation in this research study confidential to the extent permitted 
by law. However, it is possible that other people such as those indicated below may 
become aware of your participation in this study and may inspect and copy records 
pertaining to this research. Some of these records could contain information that 
personally identifies you.  
• federal government regulatory agencies,  
• Your HIV physician will be notified if a score of >16 is obtained on the CES-D 
• University representatives, to complete University responsibilities 
• Washington University’s Institutional Review Board (a committee that reviews 
and approves research studies)  
 
To help protect your confidentiality, we will assign the information you give us a code 
number. A master list linking the code number and your identity will be kept separate 
from the research data. Only the PI and people helping her will be able to see the list. All 
files will be kept in a locked room in a locked cabinet accessible only by the PI. 
If we write a report or article about this study or share the study data set with others, we 
will do so in such a way that you cannot be directly identified. 
Are there additional protections for my health information? 
 
Protected Health Information (PHI) is health information that identifies you. PHI is 
protected by federal law under HIPAA (the Health Insurance Portability and 
Accountability Act). To take part in this research, you must give the research team 
permission to use and disclose (share) your PHI for the study as explained in this consent 
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form. The research team will follow state and federal laws and may share your health 
information with the agencies and people listed under the previous section titled, “How 
will you keep my information confidential?”. 
 
Once your health information is shared with someone outside of the research team, it may 
no longer be protected by HIPAA.  
 
The research team will only use and share your information as talked about in this form. 
When possible, the research team will make sure information cannot be linked to you (de-
identified). Once information is de-identified, it may be used and shared for other 
purposes not discussed in this consent form. If you have questions or concerns about your 
privacy and the use of your PHI, please contact the University’s Privacy Officer at 866-
747-4975.  
 
Although you will not be allowed to see the study information, you may be given access to 
your health care records by contacting your health care provider.  
 
If you decide not to sign this form, it will not affect 
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.  
• any benefits to which you are entitled. 
However, it will not be possible for you to take part in the study. 
If you sign this form: 
• You authorize the use of your PHI for this research 
• Your signature and this form will not expire as long as you wish to participate. 
• You may later change your mind and not let the research team use or share your 
information (you may revoke your authorization).  
• To revoke your authorization, complete the withdrawal letter, found in the 
Participant section of the Human Research Protection Office website at 
http://hrpo.wustl.edu (or use the direct link: 
http://hrpohome.wustl.edu/participants/WithdrawalTemplate.rtf) or you may 
request that the Investigator send you a copy of the letter.      
o If you revoke your authorization: 
 The research team may only use and share information already 
collected for the study. 
 Your information may still be used and shared if necessary for 
safety reasons.  
 You will not be allowed to continue to participate in the study. 
 
IS BEING IN THIS STUDY VOLUNTARY? 
Taking part in this research study is completely voluntary. You may choose not to take 
part at all. If you decide to be in this study, you may stop participating at any time. If you 
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decide not to be in this study, or if you stop participating at any time, you won’t be 
penalized or lose any benefits for which you otherwise qualify. 
What if I decide to withdraw from the study? 
You may withdraw by telling the study team you are no longer interested in participating 
in the study.  
Will I receive new information about the study while participating?  
If we obtain any new information during this study that might affect your willingness to 
continue participating in the study, we’ll promptly provide you with that information. 
Can someone else end my participation in this study? 
Under certain circumstances, the researchers might decide to end your participation in 
this research study earlier than planned. This might happen because the study is stopped 
or cancelled. 
 WHAT IF I HAVE QUESTIONS? 
We encourage you to ask questions. If you have any questions about the research study 
itself, please contact: Judy Frain (Principal Investigator) 314.302.0875. If you feel that 
you have been harmed in any way by your participation in this study,  please contact 
Michael Klebert 314.454.0058. 
If you have questions, concerns, or complaints about your rights as a research participant 
please contact the Human Research Protection Office, 660 South Euclid Avenue, Campus 
Box 8089, St. Louis, MO  63110, (314) 633-7400, or 1-(800)-438-0445 or email 
hrpo@wusm.wustl.edu. General information about being a research participant can be 
found by clicking “Participants” on the Human Research Protection Office web site, 
http://hrpohome.wustl.edu. To offer input about your experiences as a research 
participant or to speak to someone other than the research staff, call the Human Research 
Protection Office at the number above. 
 
This consent form is not a contract. It is a written explanation of what will happen during 
the study if you decide to participate. You are not waiving any legal rights by agreeing to 
participate in this study.  
Your signature indicates that this research study has been explained to you, that your 
questions have been answered, and that you agree to take part in this study. You will 
receive a signed copy of this form. 
 
 
Do not sign this form if today’s date is after $STAMP_EXP_DT. 









(Participant's name – printed) 
 
Statement of Person Who Obtained Consent 
The information in this document has been discussed with the participant or, where 
appropriate, with the participant’s legally authorized representative. The participant has 
indicated that he or she understands the risks, benefits, and procedures involved with 








(Name of Person who Obtained Consent - printed) 
 
